EP0357150B1 - Pharmaceutical compositions - Google Patents
Pharmaceutical compositions Download PDFInfo
- Publication number
- EP0357150B1 EP0357150B1 EP89202213A EP89202213A EP0357150B1 EP 0357150 B1 EP0357150 B1 EP 0357150B1 EP 89202213 A EP89202213 A EP 89202213A EP 89202213 A EP89202213 A EP 89202213A EP 0357150 B1 EP0357150 B1 EP 0357150B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hydroxy
- rings
- iron
- hydroxypyrid
- complex according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 156
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 81
- 125000005647 linker group Chemical group 0.000 claims description 44
- 229910052742 iron Inorganic materials 0.000 claims description 43
- GGOZGYRTNQBSSA-UHFFFAOYSA-N pyridine-2,3-diol Chemical class OC1=CC=CN=C1O GGOZGYRTNQBSSA-UHFFFAOYSA-N 0.000 claims description 43
- 125000004432 carbon atom Chemical group C* 0.000 claims description 35
- 150000004698 iron complex Chemical class 0.000 claims description 31
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 24
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 18
- SNUSZUYTMHKCPM-UHFFFAOYSA-N 1-hydroxypyridin-2-one Chemical class ON1C=CC=CC1=O SNUSZUYTMHKCPM-UHFFFAOYSA-N 0.000 claims description 15
- LQUSVSANJKHVTM-UHFFFAOYSA-N 3-hydroxy-3h-pyridin-4-one Chemical class OC1C=NC=CC1=O LQUSVSANJKHVTM-UHFFFAOYSA-N 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 13
- 230000007935 neutral effect Effects 0.000 claims description 12
- 150000001450 anions Chemical class 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 150000002430 hydrocarbons Chemical class 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 7
- 239000004215 Carbon black (E152) Substances 0.000 claims description 6
- 229930195733 hydrocarbon Natural products 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- QVXIZJHZWYLVET-UHFFFAOYSA-N 3-hydroxy-2-methyl-3h-pyridin-4-one Chemical compound CC1=NC=CC(=O)C1O QVXIZJHZWYLVET-UHFFFAOYSA-N 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- GTWMLJMQDNMHEJ-UHFFFAOYSA-N 2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[4-[[2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)acetyl]-[3-[[2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)acetyl]amino]propyl]amino]butyl]acetamide Chemical compound CC1=C(O)C(=O)C=CN1CC(=O)NCCCCN(C(=O)CN1C(=C(O)C(=O)C=C1)C)CCCNC(=O)CN1C(C)=C(O)C(=O)C=C1 GTWMLJMQDNMHEJ-UHFFFAOYSA-N 0.000 claims description 2
- LSPYGUSJLGJORN-UHFFFAOYSA-N 2-(3-hydroxy-2-oxopyridin-1-yl)-n-[3-[[2-(3-hydroxy-2-oxopyridin-1-yl)acetyl]-[3-[[2-(3-hydroxy-2-oxopyridin-1-yl)acetyl]amino]propyl]amino]propyl]acetamide Chemical compound O=C1C(O)=CC=CN1CC(=O)NCCCN(C(=O)CN1C(C(O)=CC=C1)=O)CCCNC(=O)CN1C(=O)C(O)=CC=C1 LSPYGUSJLGJORN-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- TZNFJAFQHZIQTN-UHFFFAOYSA-N n-[2-[bis[2-[3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propanoylamino]ethyl]amino]ethyl]-3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propanamide Chemical compound CC1=C(O)C(=O)C=CN1CCC(=O)NCCN(CCNC(=O)CCN1C(=C(O)C(=O)C=C1)C)CCNC(=O)CCN1C(C)=C(O)C(=O)C=C1 TZNFJAFQHZIQTN-UHFFFAOYSA-N 0.000 claims description 2
- QNZKJNRJNNXADJ-UHFFFAOYSA-N n-[2-[bis[2-[[2-(3-hydroxy-2-oxopyridin-1-yl)acetyl]amino]ethyl]amino]ethyl]-2-(3-hydroxy-2-oxopyridin-1-yl)acetamide Chemical compound O=C1C(O)=CC=CN1CC(=O)NCCN(CCNC(=O)CN1C(C(O)=CC=C1)=O)CCNC(=O)CN1C(=O)C(O)=CC=C1 QNZKJNRJNNXADJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 45
- 150000002505 iron Chemical class 0.000 description 42
- 239000000203 mixture Substances 0.000 description 40
- -1 iron cation Chemical class 0.000 description 39
- 238000002360 preparation method Methods 0.000 description 32
- 239000007787 solid Substances 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Substances [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 28
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 238000006243 chemical reaction Methods 0.000 description 26
- 239000003153 chemical reaction reagent Substances 0.000 description 26
- 239000000243 solution Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 238000013459 approach Methods 0.000 description 20
- 239000003921 oil Substances 0.000 description 18
- 235000019198 oils Nutrition 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- KBPLFHHGFOOTCA-UHFFFAOYSA-N caprylic alcohol Natural products CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 11
- 125000001424 substituent group Chemical group 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000010494 dissociation reaction Methods 0.000 description 10
- 230000005593 dissociations Effects 0.000 description 10
- 210000003743 erythrocyte Anatomy 0.000 description 10
- 238000005192 partition Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 150000001768 cations Chemical class 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000002244 precipitate Substances 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 8
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 125000002947 alkylene group Chemical group 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 8
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 238000006467 substitution reaction Methods 0.000 description 8
- LQDVCPYRCOKNMV-UHFFFAOYSA-N 2-methyl-3-phenylmethoxypyran-4-one Chemical compound O1C=CC(=O)C(OCC=2C=CC=CC=2)=C1C LQDVCPYRCOKNMV-UHFFFAOYSA-N 0.000 description 7
- 229910002553 FeIII Inorganic materials 0.000 description 7
- 208000007502 anemia Diseases 0.000 description 7
- 125000000524 functional group Chemical group 0.000 description 7
- 238000001953 recrystallisation Methods 0.000 description 7
- 238000002390 rotary evaporation Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 239000006227 byproduct Substances 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 229940006199 ferric cation Drugs 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- DTSDBGVDESRKKD-UHFFFAOYSA-N n'-(2-aminoethyl)propane-1,3-diamine Chemical compound NCCCNCCN DTSDBGVDESRKKD-UHFFFAOYSA-N 0.000 description 6
- TVMXDCGIABBOFY-UHFFFAOYSA-N n-Octanol Natural products CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 6
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical class CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical class NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000008020 evaporation Effects 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 210000000813 small intestine Anatomy 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- ARFVMDGLWVUTTD-UHFFFAOYSA-N 2-(3-hydroxy-2-oxopyridin-1-yl)-n-[6-[[2-(3-hydroxy-2-oxopyridin-1-yl)acetyl]amino]hexyl]acetamide Chemical compound O=C1C(O)=CC=CN1CC(=O)NCCCCCCNC(=O)CN1C(=O)C(O)=CC=C1 ARFVMDGLWVUTTD-UHFFFAOYSA-N 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- VEYIMQVTPXPUHA-UHFFFAOYSA-N 3-hydroxypyran-4-one Chemical compound OC1=COC=CC1=O VEYIMQVTPXPUHA-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 4
- 238000005538 encapsulation Methods 0.000 description 4
- 229960002413 ferric citrate Drugs 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- PWGJDPKCLMLPJW-UHFFFAOYSA-N 1,8-diaminooctane Chemical compound NCCCCCCCCN PWGJDPKCLMLPJW-UHFFFAOYSA-N 0.000 description 3
- KGSVNOLLROCJQM-UHFFFAOYSA-N 2-(benzylamino)acetic acid Chemical compound OC(=O)CNCC1=CC=CC=C1 KGSVNOLLROCJQM-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 125000002015 acyclic group Chemical group 0.000 description 3
- 150000008431 aliphatic amides Chemical class 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 3
- 229940073608 benzyl chloride Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 150000002506 iron compounds Chemical class 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- OTBHHUPVCYLGQO-UHFFFAOYSA-N 1,7-diamino-4-aza-heptane Natural products NCCCNCCCN OTBHHUPVCYLGQO-UHFFFAOYSA-N 0.000 description 2
- WKYWXMBPGPRYKK-UHFFFAOYSA-N 2-(2-oxo-3-phenylmethoxypyridin-1-yl)acetic acid Chemical compound O=C1N(CC(=O)O)C=CC=C1OCC1=CC=CC=C1 WKYWXMBPGPRYKK-UHFFFAOYSA-N 0.000 description 2
- DXNGPENDMXMPDY-UHFFFAOYSA-N 3-(2-methyl-4-oxo-3-phenylmethoxypyridin-1-yl)propanoic acid Chemical compound O=C1C=CN(CCC(O)=O)C(C)=C1OCC1=CC=CC=C1 DXNGPENDMXMPDY-UHFFFAOYSA-N 0.000 description 2
- ZCUUVWCJGRQCMZ-UHFFFAOYSA-N 3-hydroxypyridin-4-one Natural products OC1=CC=NC=C1O ZCUUVWCJGRQCMZ-UHFFFAOYSA-N 0.000 description 2
- PNKRCBZCUWEUCW-UHFFFAOYSA-N 6-(2-methyl-4-oxo-3-phenylmethoxypyridin-1-yl)hexanoic acid Chemical compound O=C1C=CN(CCCCCC(O)=O)C(C)=C1OCC1=CC=CC=C1 PNKRCBZCUWEUCW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010065973 Iron Overload Diseases 0.000 description 2
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 2
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Chemical class CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 229940000635 beta-alanine Drugs 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000007810 chemical reaction solvent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- XSSKVHCYVBXLKS-UHFFFAOYSA-N ethyl 2-(3-hydroxy-2-oxopyridin-1-yl)acetate Chemical compound CCOC(=O)CN1C=CC=C(O)C1=O XSSKVHCYVBXLKS-UHFFFAOYSA-N 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 150000002332 glycine derivatives Chemical class 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Chemical class CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 210000001630 jejunum Anatomy 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229940043353 maltol Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003335 secondary amines Chemical group 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- MBYLVOKEDDQJDY-UHFFFAOYSA-N tris(2-aminoethyl)amine Chemical compound NCCN(CCN)CCN MBYLVOKEDDQJDY-UHFFFAOYSA-N 0.000 description 2
- OOLKQIGHCAUTTP-UHFFFAOYSA-N (4-nitrophenyl) 2-(benzylamino)acetate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)CNCC1=CC=CC=C1 OOLKQIGHCAUTTP-UHFFFAOYSA-N 0.000 description 1
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical class C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- BMLNAEBFTONATC-UHFFFAOYSA-N 2-(2-methyl-4-oxo-3-phenylmethoxypyridin-1-yl)-n-[4-[3-[[2-(2-methyl-4-oxo-3-phenylmethoxypyridin-1-yl)acetyl]amino]propylamino]butyl]acetamide Chemical compound O=C1C=CN(CC(=O)NCCCCNCCCNC(=O)CN2C(=C(OCC=3C=CC=CC=3)C(=O)C=C2)C)C(C)=C1OCC1=CC=CC=C1 BMLNAEBFTONATC-UHFFFAOYSA-N 0.000 description 1
- DQGYNYKGMAKMSU-UHFFFAOYSA-N 2-(2-methyl-4-oxo-3-phenylmethoxypyridin-1-yl)acetic acid Chemical compound O=C1C=CN(CC(O)=O)C(C)=C1OCC1=CC=CC=C1 DQGYNYKGMAKMSU-UHFFFAOYSA-N 0.000 description 1
- BRPROKDHVXSGRZ-UHFFFAOYSA-N 2-(2-oxo-3-phenylmethoxy-1h-pyridin-4-yl)propanoic acid Chemical compound C1=CNC(=O)C(OCC=2C=CC=CC=2)=C1C(C(O)=O)C BRPROKDHVXSGRZ-UHFFFAOYSA-N 0.000 description 1
- GFBVKLXUMLJEQM-UHFFFAOYSA-N 2-(2-oxo-3-phenylmethoxypyridin-1-yl)-n-[3-[[2-(2-oxo-3-phenylmethoxypyridin-1-yl)acetyl]-[3-[[2-(2-oxo-3-phenylmethoxypyridin-1-yl)acetyl]amino]propyl]amino]propyl]acetamide Chemical compound C1=CC=C(OCC=2C=CC=CC=2)C(=O)N1CC(=O)NCCCN(C(=O)CN1C(C(OCC=2C=CC=CC=2)=CC=C1)=O)CCCNC(=O)CN(C1=O)C=CC=C1OCC1=CC=CC=C1 GFBVKLXUMLJEQM-UHFFFAOYSA-N 0.000 description 1
- VGWOHQFXUWVFRW-UHFFFAOYSA-N 2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[2-[[2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)acetyl]amino]ethyl]acetamide Chemical compound CC1=C(O)C(=O)C=CN1CC(=O)NCCNC(=O)CN1C(C)=C(O)C(=O)C=C1 VGWOHQFXUWVFRW-UHFFFAOYSA-N 0.000 description 1
- LNNMPJGVSGVXSD-UHFFFAOYSA-N 2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[3-[2-[[2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)acetyl]amino]ethylamino]propyl]acetamide Chemical compound CC1=C(O)C(=O)C=CN1CC(=O)NCCCNCCNC(=O)CN1C(C)=C(O)C(=O)C=C1 LNNMPJGVSGVXSD-UHFFFAOYSA-N 0.000 description 1
- WUDHYNGBCMZNKE-UHFFFAOYSA-N 2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[3-[[2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)acetyl]-[2-[[2-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)acetyl]amino]ethyl]amino]propyl]acetamide Chemical compound CC1=C(O)C(=O)C=CN1CC(=O)NCCCN(C(=O)CN1C(=C(O)C(=O)C=C1)C)CCNC(=O)CN1C(C)=C(O)C(=O)C=C1 WUDHYNGBCMZNKE-UHFFFAOYSA-N 0.000 description 1
- KRMTWTYSUMHDCB-UHFFFAOYSA-N 2-(benzylamino)-n-[3-[2-[[2-(benzylamino)acetyl]amino]ethylamino]propyl]acetamide Chemical compound C=1C=CC=CC=1CNCC(=O)NCCNCCCNC(=O)CNCC1=CC=CC=C1 KRMTWTYSUMHDCB-UHFFFAOYSA-N 0.000 description 1
- DSZWMXDYNPEINK-UHFFFAOYSA-N 2-(benzylamino)-n-[3-[[2-(benzylamino)acetyl]-[2-[[2-(benzylamino)acetyl]amino]ethyl]amino]propyl]acetamide Chemical compound C=1C=CC=CC=1CNCC(=O)NCCN(C(=O)CNCC=1C=CC=CC=1)CCCNC(=O)CNCC1=CC=CC=C1 DSZWMXDYNPEINK-UHFFFAOYSA-N 0.000 description 1
- NXNPMLRVBRTGQJ-UHFFFAOYSA-N 2-(benzylamino)-n-[4-[[2-(benzylamino)acetyl]-[3-[[2-(benzylamino)acetyl]amino]propyl]amino]butyl]acetamide Chemical compound C=1C=CC=CC=1CNCC(=O)NCCCN(C(=O)CNCC=1C=CC=CC=1)CCCCNC(=O)CNCC1=CC=CC=C1 NXNPMLRVBRTGQJ-UHFFFAOYSA-N 0.000 description 1
- OXXDGKNPRNPMLS-UHFFFAOYSA-N 2-Hydroxy-3-methyl-4H-pyran-4-one Natural products CC1=C(O)OC=CC1=O OXXDGKNPRNPMLS-UHFFFAOYSA-N 0.000 description 1
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 1
- XJFVDBFABYBRAP-UHFFFAOYSA-N 2-amino-n-[3-[2-[(2-aminoacetyl)amino]ethylamino]propyl]acetamide Chemical compound NCC(=O)NCCCNCCNC(=O)CN XJFVDBFABYBRAP-UHFFFAOYSA-N 0.000 description 1
- LEMIVSOYTJOQTC-UHFFFAOYSA-N 2-amino-n-[3-[[(2-aminoacetyl)amino]-[2-[(2-aminoacetyl)amino]ethyl]amino]propyl]acetamide Chemical compound NCC(=O)NCCCN(NC(=O)CN)CCNC(=O)CN LEMIVSOYTJOQTC-UHFFFAOYSA-N 0.000 description 1
- PBGQULXHQYAWSJ-UHFFFAOYSA-N 2-amino-n-[4-[[(2-aminoacetyl)amino]-[3-[(2-aminoacetyl)amino]propyl]amino]butyl]acetamide Chemical compound NCC(=O)NCCCCN(NC(=O)CN)CCCNC(=O)CN PBGQULXHQYAWSJ-UHFFFAOYSA-N 0.000 description 1
- YSTCMHHKDOVZDA-UHFFFAOYSA-N 2-chloro-4-nitro-1-oxidopyridin-1-ium Chemical compound [O-][N+](=O)C1=CC=[N+]([O-])C(Cl)=C1 YSTCMHHKDOVZDA-UHFFFAOYSA-N 0.000 description 1
- DVBDAPRLRNKNAH-UHFFFAOYSA-N 3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[4-[3-[3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propanoylamino]propylamino]butyl]propanamide Chemical compound CC1=C(O)C(=O)C=CN1CCC(=O)NCCCCNCCCNC(=O)CCN1C(C)=C(O)C(=O)C=C1 DVBDAPRLRNKNAH-UHFFFAOYSA-N 0.000 description 1
- KWBXZNSPVOXCLO-UHFFFAOYSA-N 3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[8-[3-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)propanoylamino]octyl]propanamide Chemical compound CC1=C(O)C(=O)C=CN1CCC(=O)NCCCCCCCCNC(=O)CCN1C(C)=C(O)C(=O)C=C1 KWBXZNSPVOXCLO-UHFFFAOYSA-N 0.000 description 1
- FUTWXOBEAYKVDA-UHFFFAOYSA-N 3-hydroxy-1-[8-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)octyl]-2-methylpyridin-4-one Chemical compound CC1=C(O)C(=O)C=CN1CCCCCCCCN1C(C)=C(O)C(=O)C=C1 FUTWXOBEAYKVDA-UHFFFAOYSA-N 0.000 description 1
- QBJZIBMLIQHZBF-UHFFFAOYSA-N 3-hydroxy-1-[9-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)nonyl]-2-methylpyridin-4-one Chemical compound CC1=C(O)C(=O)C=CN1CCCCCCCCCN1C(C)=C(O)C(=O)C=C1 QBJZIBMLIQHZBF-UHFFFAOYSA-N 0.000 description 1
- MKMZYQOQNQAGSX-UHFFFAOYSA-N 3-phenylmethoxypyran-4-one Chemical compound O=C1C=COC=C1OCC1=CC=CC=C1 MKMZYQOQNQAGSX-UHFFFAOYSA-N 0.000 description 1
- VZIVTTKRKULOLO-UHFFFAOYSA-N 4-(2-methyl-4-oxo-3-phenylmethoxypyridin-1-yl)butanoic acid Chemical compound O=C1C=CN(CCCC(O)=O)C(C)=C1OCC1=CC=CC=C1 VZIVTTKRKULOLO-UHFFFAOYSA-N 0.000 description 1
- MFFHDWCAFTYZFD-UHFFFAOYSA-N 4-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[2-[4-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)butanoylamino]ethyl]butanamide Chemical compound CC1=C(O)C(=O)C=CN1CCCC(=O)NCCNC(=O)CCCN1C(C)=C(O)C(=O)C=C1 MFFHDWCAFTYZFD-UHFFFAOYSA-N 0.000 description 1
- IMDZPCKZALMYID-UHFFFAOYSA-N 6-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)-n-[2-[6-(3-hydroxy-2-methyl-4-oxopyridin-1-yl)hexanoylamino]ethyl]hexanamide Chemical compound CC1=C(O)C(=O)C=CN1CCCCCC(=O)NCCNC(=O)CCCCCN1C(C)=C(O)C(=O)C=C1 IMDZPCKZALMYID-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-O Htris Chemical compound OCC([NH3+])(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-O 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- JVHZMYAXZUIZKS-UHFFFAOYSA-N OC1=CC=CC=[N+]1[O-] Chemical class OC1=CC=CC=[N+]1[O-] JVHZMYAXZUIZKS-UHFFFAOYSA-N 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- CVQUWLDCFXOXEN-UHFFFAOYSA-N Pyran-4-one Chemical compound O=C1C=COC=C1 CVQUWLDCFXOXEN-UHFFFAOYSA-N 0.000 description 1
- 241000786363 Rhampholeon spectrum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000002431 aminoalkoxy group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 150000001555 benzenes Chemical group 0.000 description 1
- 238000005574 benzylation reaction Methods 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000005111 carboxyalkoxy group Chemical group 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 238000006264 debenzylation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000000797 iron chelating agent Substances 0.000 description 1
- 229940075525 iron chelating agent Drugs 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- SXJVFQLYZSNZBT-UHFFFAOYSA-N nonane-1,9-diamine Chemical compound NCCCCCCCCCN SXJVFQLYZSNZBT-UHFFFAOYSA-N 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 208000004003 siderosis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940063673 spermidine Drugs 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
Definitions
- This invention relates to iron complexes for use in pharmaceutical compositions.
- iron deficiency anaemia is commonly encountered in pregnancy and may also present a problem in the newly born, particularly in certain animal species such as the pig.
- pathological conditions there is a maldistribution of body iron leading to a state of chronic anaemia. This is seen in chronic diseases such as rheumatoid arthritis, certain haemolytic diseases and cancer.
- iron compounds Although a wide range of iron compounds is already marketed for the treatment of iron deficiency anaemia, the level of iron uptake by the body from these compounds is often quite low, necessitating the administration of relatively high dosage levels of the compound.
- the administration of high dose, poorly absorbed, iron complexes may cause siderosis of the gut wall and a variety of side effects such as nausea, vomiting, constipation and heavy malodorous stools.
- We have now found that the iron complexes of certain hydroxypyridone compounds are of particular value in the treatment of iron deficiency anaemia (in the broad sense of this term).
- the present invention comprises an iron complex of a compound in which 2 or more rings, being a 3-hydroxypyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxypyrid-2-one, are linked.
- hydroxypyridone rings in compounds providing iron complexes according to the present invention may be identical or may differ, either varying between the three forms of hydroxypyridone and/or, since the ring may be substituted, between differing rings of the same basic form. In general, however, there is little advantage to be gained from the presence of dissimilar rings and this can complicate the synthesis of the compound so that it is preferred that each hydroxypyridone ring in the compound is of the same one of the three forms and conveniently that each ring possesses the same substitution or lack of substitution.
- compounds providing iron complexes according to the present invention may contain varying numbers of rings, for example up to 10 or even 100, compounds containing 2, 3 or 4 rings are of particular interest with the 3 ring compounds being of especial use for the preparation of complexes for use in the treatment of iron deficiency anaemia.
- the iron complexes of the present invention preferably contain iron in the ferric state. Although the use of complexes containing iron in the ferrous state may be considered, such complexes tend to be less stable and are thus of less interest.
- the iron complexes are preferably neutral, i.e. there being an internal balance of charges between the metal cation or cations and the ligand or ligands bound covalently thereto without the necessity for the presence of a non-covalently bound ion or ions, for example a chloride ion, to achieve balance.
- linked hydroxpyridones containing ionisable substituent groups is of less interest and it is preferred that this internal balance of charges is achieved by complexing with an iron cation or cations a compound containing the appropriate number of hydroxypyridone rings to thereby provide, by the loss of a hydroxy proton from each ring, the number of anionic groups O ⁇ necessary to neutralise the charge on the cation or cations.
- neutrality may be achieved, for example, in a complex containing a 3:2 molar proportion of an anion from a two ring compound:iron(lII), preferred neutral complexes of this type are those formed between the anion derived from a compound containing three, or a multiple of three, hydroxypyridone rings and a ferric cation, or the same multiple of ferric cations, particularly those containing a trivalent anion derived from a three ring compound and a single ferric cation.
- the invention does not exclude the use of complexes in which the charge on the anion derived from the linked hydroxypyridone compound and that on the ferric cation or cations do not fully neutralise each other, for example owing to the presence of an ionisable linking group, so that association with a further non-covalently bound physiologically acceptable ion or ions is necessary to achieve a balance of charges, although such complexes are generally of lesser interest.
- the present invention thus particularly includes a neutral iron complex containing 1 molar proportion of iron(III) and 1 molar proportion of a compound as defined hereinbefore in which three rings are linked.
- neutral iron complexes according to the present invention is discussed hereinafter with particular reference to such 1:1 complexes.
- preferred compounds show a value of K part for the free compound of above 0.02 but less than 3.0, especially of above 0.2 but less than 1.0, together with a value of K part for the smallest neutral iron(III) complex in which there is an internal balance of charges of above 0.02 but less than 6.0, especially of above 0.2 but less than 1.0.
- K part for the free compound of above 0.02 but less than 3.0, especially of above 0.2 but less than 1.0
- K part for the smallest neutral iron(III) complex in which there is an internal balance of charges of above 0.02 but less than 6.0, especially of above 0.2 but less than 1.0.
- this smallest neutral iron(III) complex will contain 3 molar proportions of the compound:2 molar proportions of iron(III) but for the preferred iron binding compounds containing three rings the complex will contain a 1:1 molar ratio of compound:iron(III).]
- K part is less critical.
- the hydroxypyridone rings may, for example, be substituted as discussed for the metal-free single ring compounds in UK patent applications 8308056 (published as GB 2118176A), 8407181 (published as GB 2136807A) and 8423800 (published as GB 2146990A), the equivalent European applications being A-0 093 498, A-0 094 149 and A-0 138 420, respectively, allowing for the necessity to provide a point of linkage for the various rings so that, for example, if the rings are linked through the nitrogen atoms thereof then this position of the ring may not be otherwise substituted.
- Examples of types of substitution additional to the linking groups thus include, for 3-hydroxypyrid-2-one and 3-hydroxypyrid-4-one rings, replacement of the hydrogen atom attached to the nitrogen atom by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and/or replacement of one or more of the hydrogen atoms attached to ring carbon atoms by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; and for 1-hydroxypyrid-2-one rings, replacement of one or more of the hydrogen atoms attached to ring carbon atoms by
- the 3-hydroxypyrid-2- and -4-one rings are preferably linked through the nitrogen atoms thereof and the hydroxy group on the nitrogen atoms of the 1-hydroxypyrid-2-ones is required for iron binding, such substitution as is present is more usually limited to the carbon atoms of the ring and is preferably limited to aliphatic hydrocarbon substituent groups.
- substitution as is present is more usually limited to the carbon atoms of the ring and is preferably limited to aliphatic hydrocarbon substituent groups.
- more than one of the ring carbon atoms may be substituted, for example two of such atoms, either by the same or different substituent groups, compounds in which only one, or none, of the ring carbon atoms are substituted are preferred.
- Substitution may occur at various positions of the ring but, particularly when the ring carbon atoms are substituted by the larger groups, there may be an advantage in avoiding substitution on a carbon atom alpha to the system.
- These systems are involved in the complexing of the compound with iron and other metals and the close proximity of one of the larger groups may lead to steric effects which inhibit complex formation.
- a ring being substituted by an aliphatic hydrocarbon group it will be appreciated that this term is used herein to include both acyclic and cyclic groups which may be unsaturated or especially saturated, the acyclic groups having a branched chain or especially a straight chain. Groups of from 1 to 6 carbon atoms, particularly of 1 to 4 and especially of 1 to 3 carbon atoms, are of most interest. Saturated aliphatic hydrocarbon groups are preferred, these being either cyclic groups such as the cycloalkyl groups cyclopropyl and especially cyclohexyl or, more particularly, acyclic groups such as the alkyl groups methyl, ethyl, n-propyl and isopropyl.
- aliphatic hydrocarbon group substituents in the context of the present invention lies, however, in the possibility of using single ring compounds containing such a substituent on one or more carbon atoms thereof as being a more readily available starting material than the corresponding unsubstituted compound for the preparation of the multi-ring compounds.
- methyl substituent groups are of particular interest and have the advantage of not being so large as to create the problems referred to above.
- 3-hydroxypyrid-4-ones where the use of methyl substituted compounds as starting materials is of most relevance, it is likely for reasons of availability that any methyl substituent will in fact be located at the 2- or 6-position.
- Preferred ring systems present in the compounds providing iron complexes of the present invention are shown below, the free valency in each case indicating the preferred point of attachment of the linking group between one ring and another (it will be appreciated that the 1-hydroxypyrid-2-ones are tautomeric compounds, being alteratively named as 2-hydroxypyridine-1-oxides).
- the hydroxypyridone rings may be linked through various types of linking group, the important feature of the compounds being the rings contained therein and the nature of the linking groups therefore being of lesser importance.
- Linking groups which are either wholly of a hydrocarbon nature or which additionally contain one or more of the same or different groups selected from -O-, -S-, -NH-, -CONH- and -CON ⁇ are of value by virtue of the ease of synthesis and non-interference in the metal complexing action of the compounds.
- linking hydrocarbon linking groups are a benzene group substituted by two or more methylene groups, and various aliphatic hydrocarbon groups.
- the latter may conveniently contain between 6 and 18 or 24 carbon atoms, especially between 6 or 8 and 12 carbon atoms, and when used in two ring compounds, where they are particularly useful, are preferably straight chain alkylene groups, although when used as a single linking group in compounds containing more than two rings they must necessarily be branched.
- Specific examples of such straight chain alkylene groups are groups -(CH2) n - in which n is an integer from 6 to 12, for example 8, 9 or 10.
- linking groups of especial interest are groups corresponding to a hydrocarbon group in which one or more carbon atoms are replaced by a nitrogen atom and/or in which one or more pairs of adjacent carbon atoms are replaced by a -CONH- group.
- Such groups are preferably of similar overall size (i.e. contain a similar total number of atoms in the backbone or chain thereof) to the hydrocarbon groups described above.
- Certain of such groups are of particular interest in the context of divalent linking groups for use in two ring compounds. These divalent groups may conveniently correspond to a straight chain alkylene group in which one carbon atom is replaced by a -NH- group and/or in which two pairs of adjacent carbon atoms are replaced by a -CONH- group.
- linking groups in the case of (2) it is preferred that 4 ⁇ 2 c + d ⁇ 12 and in the case of (3) it is preferred that 6 ⁇ 2 c + e + f ⁇ 12 .
- the linking groups used may often correspond to those described above but with an additional oxy group at each terminus thereof.
- Trivalent linking groups of use in the present invention in the preparation of three ring compounds may include both the hydrocarbon and modified hydrocarbon types referred to hereinbefore. They are often similar to the divalent linking groups described above, modified so as to have three parts each terminating in a free valency arranged about the centre of the linking group instead of two.
- Groups of especial interest are a benzene group which is 1,3,5-substituted by three methylene groups and tripod groups consisting of a nitrogen atom substituted by three alkylene groups, for example straight chain groups of 1 to 6 carbon atoms and particularly 4 or 5 carbon atoms, or similar substituted benzene groups or tripod groups in which the methylene or alkylene groups are terminally substituted by a group -NHCO-(CH2) c - wherein c is as defined hereinbefore.
- the three alkylene groups attached to the nitrogen atom of the tripod group may generally be somewhat shorter than previously indicated, preferably being straight chain and conveniently being of 1 to 4 carbon atoms, particularly of 2 or 3 carbon atoms when c is 1, for example of 2 carbon atoms each or of 2, 3 and 3 carbon atoms, respectively.
- the trivalent group may be viewed as corresponding to a branched, trivalent hydrocarbon group in which a ⁇ CH group is replaced by ⁇ N and three pairs of adjacent carbon atoms are replaced by a -CONH- group.
- they may be viewed in a closer analogy to the divalent groups as corresponding to a straight chain alkylene group in which a -CH2- group is replaced by a ⁇ N-CO(CH2) g - group wherein g is an integer from 1 to 3, especially being 1, and two pairs of carbon atoms are replaced by a -CONH- group.
- linking groups will often contain a nitrogen atom in a substantially central position in the chain and/or one amido group located adjacent to each end of the chain, the carbonyl group thereof often being bonded to the terminal or penultimate carbon atom of the chain.
- linking groups these may with particular convenience contain a fully branched carbon atom which may be attached to four groups which are either wholly of a hydrocarbon nature or which additionally contain other groups such as those described hereinbefore.
- the compounds providing iron complexes according to the present invention may be synthesised using various different approaches.
- linkage is usually effected through the nitrogen atom of the ring.
- One approach which is particularly applicable to the 3-hydroxypyrid-2-ones, involves reaction of the 3-hydroxypyridone, in a suitable proportion, with a reagent providing the linking group which contains the appropriate number of functional groups capable of reaction with the -NH- group of the pyridone. This procedure is of particular interest for the preparation of two ring compounds and suitable functional groups include the iodo group.
- a second approach involves reaction of a 3-hydroxypyridone which is N-substituted by a substituent containing a suitable first functional group with a reagent containing suitable second functional groups for reaction with said first group, the linking group deriving from both the N-substituent and the reagent.
- the procedure is of particular application for both the 3-hydrox-pyrid-2- and -4-ones in the preparation of two ring and three ring compounds, and suitable functional groups include a combination of a carboxy group and an amino group, either one of which may be attached to the 3-hydroxypyridone and the other of which to the reagent.
- the hydroxypyridone may, for example, be N-substituted by a group -(CH2) i -CO2H or -(CH2) i -NH2 wherein i is an integer from 1 to 5, for example 1, 2 or 3.
- the reagent in the former case which is the preferred one, may be a di- or tri-amine, etc., and in the later case a di- or tri-carboxylic acid, although it will be appreciated that it is usual, whether the carboxy group is on the hydroxypyridone or the reagent, to activate it before reaction.
- Such activation may, for example, involve the use of an activated ester such as the p-nitrophenyl or 1-succinimyl ester and it will be usual to protect the ring hydroxy group, for example by benzylation, to prevent reaction thereof with the activated ester group or other form of activated carboxy group.
- an activated ester such as the p-nitrophenyl or 1-succinimyl ester
- it will be usual to protect the ring hydroxy group for example by benzylation, to prevent reaction thereof with the activated ester group or other form of activated carboxy group.
- 3-hydroxypyrid-4-ones where it is possible to react a di- or tri-amine, with a protected 3-hydroxy-4-pyrone, for example a 3-benzyloxy-4-pyrone, to replace the ring oxygen atom by a nitrogen atom of the reagent and thus effect linkage of two, three or more rings.
- a protected 3-hydroxy-4-pyrone for example a 3-benzyloxy-4-pyrone
- Certain 3-hydroxy-4-pyrones such as the unsubstituted compound and the 2-methyl substituted compound, maltol, are available commercially.
- Other readily available compounds include the 6-methyl substituted compound, isomaltol, and other 2-alkyl substituted compounds whose synthesis is described in US application serial number 310,141 (series of 1960).
- a specific example of such a first approach as described above involves the use of a reagent I-(CH2) n -I, wherein n is as defined hereinbefore, and the reagent C-( CH2Br)4 to prepare compounds containing two or four linked 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one rings, respectively, for example the rings (I) and (III) as shown hereinbefore.
- Such reagents are used to prepare compounds containing two or three linked rings by reaction with a 3-hydroxypyrid-2- or -4-one, for example a compound corresponding to one of the formulae (I) to (IV) as shown hereinbefore, with an N-substituent, for example a group -CH2CO2H, -(CH2)2-CO2H, -(CH2)3-CO2H, -(CH2)4-CO2H or -(CH2)5-CO2H in activated form.
- an N-substituent for example a group -CH2CO2H, -(CH2)2-CO2H, -(CH2)3-CO2H, -(CH2)4-CO2H or -(CH2)5-CO2H in activated form.
- linking groups described above are preferred in the case of certain types of hydroxypyridone and also that, in some instances, the same type of linking group may be produced by different approaches so that, for example, an amido function in the linking group may be present in the reagent used to form that group or may be produced by the reaction of an amine group and an activated ester group, one of which is attached to the reagent and the other to the hydroxypyridone ring.
- an amido function in the linking group may be present in the reagent used to form that group or may be produced by the reaction of an amine group and an activated ester group, one of which is attached to the reagent and the other to the hydroxypyridone ring.
- the selection of a synthetic route for the preparation of a particular compound will depend on various factors, including the relative availability of suitable intermediates.
- the present invention extends to the various compounds, per se , obtainable using the specific reagents referred to above in connection with the second approach for the linking of 3-hydroxypyrid-2- and -4-ones when used in conjuction with a 1-hydroxypyrid-2-one which is C-substituted by a group -O-(CH2) i -CO2H or -O-(CH2) i -NH2, wherein i is as defined hereinbefore and is preferably greater than 1 in the case of the latter type of group.
- the carboxy group will be in activated form in the former case, and both types of group may conveniently be substituted at the 4-position of the 1-hydroxypyrid-2-one.
- the amine N-(2-aminoethyl)-1,3-propanediamine used in Example 6 may be reacted, as described in the footnote (1)(A) and (B) to that Example, with a glycine derivative in which the carboxy group is in activated ester form and the amino group is protected, for example as N-benzylglycine p-nitrophenyl ester, to provide, after removal of the N-protecting group, the compound H2N-CH2CONH-(CH2)2-NH-(CH2)3-NHCOCH2-NH2 or the compound H2N-CH2CONH-(CH2)2-N(COCH2-NH2)-(CH2)3-NHCOCO2-NH2, depending on the conditions used.
- a glycine derivative in which the carboxy group is in activated ester form and the amino group is protected for example as N-benzylglycine p-nitrophenyl ester
- the former compound will precipitate from the reaction mixture and the latter compound is not formed even in the presence of a three, rather than two, molar proportion of the glycine derivative.
- a more polar solvent such as dimethylformamide
- a three molar proportion will lead to the formation of the latter compound.
- the former compound may be used as such in the preparation of two ring compounds or, alternatively, may be reacted in a solvent such as dimethylformamide with another amino acid.
- reaction with a suitable ⁇ -alanine derivative for example, will lead to the formation of the compound H2N-CH2CONH-(CH2)2-N(COCH2CH2-NH2)-(CH2)3-NHCOCH2-NH2.
- the iron complexes are conveniently prepared by the reaction of the linked hydroxypyridone compound and iron ions, the latter conveniently being derived from an iron salt, particularly a ferric halide and especially ferric chloride.
- the reaction is conveniently effected in a suitable mutual solvent and water may often be used for this purpose.
- an aqueous/organic solvent mixture may be used or an organic solvent, for example ethanol, methanol, chloroform and mixtures of these solvents together and/or with water where appropriate.
- methanol or especially ethanol may be used as the solvent where it is desired to effect the separation of at least a major part of a by-product such as sodium chloride by precipitation whilst the iron complex is retained in solution.
- Alternative procedures may, however, be used and will be apparent to those skilled in the art.
- the nature of the iron complex obtained by the reaction of a linked hydroxypyridone compound and iron ions will depend both on the proportion of these two reactants and upon the pH of the reaction medium.
- the linked three ring hydroxypyridone compound and the ferric salt are conveniently mixed in solution in a 1:1 molar proportion and the pH adjusted to a value in the range of 6 to 9, for example 7 or 8.
- Adjustment of the pH may conveniently be effected by the addition either of sodium carbonate or of a hydroxide base such as sodium or ammonium hydroxide, the use of a hydroxide base being of particular interest when preparing the iron complexes in batches of 20 g or more.
- the reaction may conveniently be carried out in a medium containing water as the solvent, for example in water or an ethanol:water mixture, and the pH adjusted by the addition of a 2 molar aqueous solution of the base.
- a medium containing water for example in water or an ethanol:water mixture
- the pH adjusted by the addition of a 2 molar aqueous solution of the base will be appreciated that the presence of water in the reaction mixture will lead to the retention of a by-product in the iron complex on evaporation of the solvent (a chloride where the iron salt is ferric chloride).
- this can be removed, if desired, by procedures such as crystallisation from a suitable solvent system or sublimation in the particular case of ammonium chloride.
- reaction to form the iron complex is generally rapid and will usually have proceeded substantially to completion after 5 minutes at about 20°C, although a longer reaction time may be used if necessary.
- the reaction mixture may conveniently be evaporated on a rotary evaporator or freeze dried to yield the solid iron complex.
- This may, if desired, be crystallised from a suitable solvent, for example water, an alcohol such as ethanol, or a solvent mixture, including mixtures containing an ether.
- the present invention thus further includes a process for the preparation of an iron complex of a linked hydroxypyridone compound as defined hereinbefore which comprises reacting said compound with iron ions and isolating the resultant complex.
- the iron complex Whilst for some uses it may be appropriate to prepare the iron complex in substantially pure form, i.e. substantially free from by-products of manufacture, in other cases, for example with a solid oral formulation as described hereinafter, the presence of by-products such as sodium chloride may be quite acceptable. In general, however, the neutral 1:1 [linked hydroxypyridone compound: iron(III)] complex is of particular interest in a form free from by-products which are complexes containing different proportions of hydroxypyridone and iron.
- the iron complex may be used in admixture with the metal-free linked hydroxypyridone compound and, if desired, such a mixture may be obtained directly by reacting a molar proportion of the compound and iron ions of greater than 1:1.
- the complexes may be formulated for use as pharmaceuticals for veterinary, for example in an avian or especially a mammalian context, or particularly human use by a variety of methods. For instance, they may be applied as an aqueous, oily or emulsified composition incorporating a liquid diluent which most usually will be employed for parenteral administration and therefore will be sterile and pyrogen free.
- compositions incorporating a liquid diluent may also be used for oral administration, it is preferred to use compositions incorporating a solid carrier, for example a conventional solid carrier material such as starch, lactose, dextrin or magnesium stearate, the oral composition then conveniently being of a formed type, for example as tablets capsules, (including spansules), etc.
- a solid carrier for example a conventional solid carrier material such as starch, lactose, dextrin or magnesium stearate
- the oral composition then conveniently being of a formed type, for example as tablets capsules, (including spansules), etc.
- the iron complexes may especially be applied by parenteral administration, particularly in the context of animal treatment.
- the problems of iron deficiency anaemia in newly born pigs arise primarily during the first three weeks or so of their life when a very rapid weight gain takes place.
- the iron complexes of the present invention may be used to treat piglets directly by a parenteral route, for example intramuscular, or oral, for example as a liquid preparation "injected into the mouth".
- a parenteral route for example intramuscular, or oral
- an alternative approach is to enhance the iron content of the milk on which the piglets are feeding by treating the mother pig using oral or parenteral administration, for example an injectable slow release preparation (such an approach may also be of interest in a human context).
- an injectable slow release preparation such an approach may also be of interest in a human context.
- compositions may be formulated in unit dosage form, i.e. in the form of discrete portions each comprising a unit dose, or a multiple or sub-multiple of a unit dose.
- dosage of active compound given will depend on various factors, including the particular compound which is employed in the composition, it may be stated by way of guidance, however, that maintenance of the amount of iron present in the human body at a satisfactory level will often be achieved using a daily dosage, in terms of the iron content of the compound, which lies in a range from about 0.1 to 100 mg and often in a range from 0.5 to 10 mg, for example 1 or 2 mg, veterinary doses being on a similar g/Kg body weight ratio.
- the aim should be to provide the amount of iron required by the patient without administering any undue excess and the properties of the pharmaceutical compositions according to the present invention are particularly suited to the achievement of this aim.
- an iron complex of more than one linked hydroxypyridone compound as described above may be present in the pharmaceutical composition or indeed other active compounds may be included in the composition, for example compounds having the ability to facilitate the treatment of anaemia, such as folic acid.
- Another additional component which may be included in the composition, if desired, is a source of zinc.
- Iron compounds used in the treatment of iron deficiency anaemia can inhibit the mechanism of zinc uptake in the body and this can cause serious side effects in the foetus when treating anaemia in a pregnant female. It is believed, however, that the iron complexes of the present invention have a further advantage in that they either do not have this effect or exhibit the effect at a lower level than the compounds at present used in the treatment of anaemia. Accordingly, it may often be the case that the level of zinc providing compound added to the composition may not require to be high or, with preferred formulations of the iron complexes, may be dispensed with altogether.
- iron complexes described herein are of value in the treatment of iron deficiency anaemia both in humans and also in a veterinary context, particularly for the treatment of various mammalian species and especially pigs.
- the complexes will partition into n-octanol indicating that they are able to permeate biological membranes, this property being confirmed in practice by tests of the ability of the 59Fe labelled iron complexes to permeate erythrocytes.
- the ability of the compounds in this respect will depend on the nature of the substituent(s) present therein and the reflection of this ability in the K part values of various compounds has been referred to hereinbefore.
- the complexes will donate iron to transferrin, a position of equilibrium being set up between the complexes and transferrin. It is because of the existence of this equilibrium that the corresponding metal-free linked hydroxypyridone compound may equally be used in the treatment of iron overload, although certain of these compounds may be of particular value for use in the free state for iron removal and others may be of particular value for use as iron complexes for iron supply.
- Such an approach may involve various types of controlled release system, ranging from one, which may for example be based on a polymer, which simply provides a delayed release of the complex with time, through a system which is resistant to dissociation under acidic conditions, for example by the use of buffering, to a system which and is biased towards release under conditions such as prevail in the small intestine, for example a pH sensitive system which is stabilised towards a pH of 1 to 3 such as prevails in the stomach but not one of 7 to 9 such as prevails in the small intestine. Since the pH of the stomach is higher after a meal, it may be advantageous, whatever method of formulation is used, to administer the iron complexes at such a time.
- a particularly convenient approach to a controlled release composition involves encapsulating the iron complex by a material which is resistant to dissociation in the stomach but which is adapted towards dissociation in the small intestine (or possibly, if the dissociation is slow, in the large intestine).
- Such encapsulation may be achieved with liposomes, phospholipids generally being resistant to dissociation under acidic conditions.
- the liposomally entrapped 1:1 iron(III) complexes can therefore survive the acid environment of the stomach without dissociation.
- the pancreatic enzymes On entry into the small intestine, the pancreatic enzymes rapidly destroy the phospholipid-dependent structure of the liposomes thereby releasing the 1:1 complex. Liposome disruption is further facilitated by the presence of bile salts.
- This coating protects the gelatin capsule from the action of water under the acid conditions of the stomach where the coating is protonated and therefore stable.
- the coating is however destabilised under the neutral/alkaline conditions of the intestine where it is not protonated, thereby allowing water to act on the gelatin.
- the rate of permeation of the intestine wall by the water soluble 1:1 iron(III) complex is relatively constant irrespective of the position within the intestine, i.e. whether in the jejunum, ileum or large intestine.
- Other examples of methods of formulation which may be used include the use of polymeric hydrogel formulations which do not actually encapsulate the iron complex but which are resistant to dissociation under acidic conditions.
- Another aspect of the formulation of the iron complexes to confer certain particular advantages is the use of a metal-free linked hydroxypyridone compound in admixture with its iron complex.
- a metal-free linked hydroxypyridone compound in admixture with its iron complex.
- the linked hydroxypyridone compound present in an iron donor is preferable for the linked hydroxypyridone compound present in an iron donor to be rapidly metabolized so as to effect its removal from the system once it has given up its iron at an appropriate site in the system, whilst it is preferable for a linked hydroxypyridone compound being used as an iron remover not to be rapidly metabolized so that it remains in the system, taking up iron, for an extended period.
- the use of different linked hydroxypyridone compounds in the free form and as the iron complex has certain advantages.
- different compounds may, for other reasons, function more efficiently either in the free form as an iron remover or in complex form as an iron donor.
- the free compound may alternatively be used in the form of a salt formed with the anion produced by the loss of a hydroxy proton and containing a physiologically acceptable cation.
- the iron complex may be used in combination with another iron chelating agent.
- the daily dosage of the iron complex may be as previously described and the daily dosage of the free compound may also be that described in relation to the use of such compounds in iron overload conditions.
- iron complexes In addition to the pharmaceutical uses of the iron complexes discussed above they are also of potential interest as a source of iron in various other contexts including in cell and bacterial growth, in plant growth, as a colouring agent and in the control of iron transport across membranes.
- Example 11 relates to partition data on both the iron complexes of linked 3-hydroxypyridones and the corresponding metal-free linked 3-hydroxypyridones
- Examples 1 to 10 relate to the preparation of metal-free linked hydroxypyridones of use in the preparation of iron complexes according to the present invention.
- These Examples 1 to 10 describe the preparation of various compounds of the form wherein R, R′ and R ⁇ each represent a substituted or unsubstituted 3-hydroxypyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxypyrid-2-one ring, n represents 0 or an integer 1, 2, 3, 4 etc. (no rings R ⁇ being present when n is 0) and L represents a linking group.
- the exemplified compounds contain two or three 3-hydroxypyrid-2-one or 3-hydroxy-2-methylpyrid-4-one rings joined by a variety of linking groups.
- the different compounds described in the Examples are illustrated in Table 1, the numbering of the compounds corresponding to that of the Examples. It will be appreciated that further compounds may be produced by using in the procedures of Examples 2, 3, 7 and 9 the corresponding 3-hydroxypyrid-2-one reagent with the same linking group reagents as described in these Examples and in the procedures of Examples 4, 5, 8 and 10 the corresponding 3-hydroxy-2-methylpyrid-4-one reagent with the same linking reagents as described in these Examples.
- Such further specific compounds comprising 3-hydroxypyrid-2-one rings with a linking group such as is present in compounds 2, 3, 7 and 9 and 3-hydroxy-2-methylpyrid-4-one rings with a linking group such as is present in compounds 4, 5, 8 and 10 are thus also individually included within the scope of the present invention.
- Example 7 where methylene chloride is used, the secondary amine group in the reactant does not react with the active ester, while in Example 8 where the more polar dimethylformamide is used as the solvent, the secondary amine group in the reactant does react with the active ester.
- Example 8 where the more polar dimethylformamide is used as the solvent, the secondary amine group in the reactant does react with the active ester.
- reaction mixture is then rotary evaporated to yield an oil which is dissolved in ethanol (30 ml) and hydrogenated over a palladium/charcoal catalyst. Evaporation of the solution remaining after separation of the catalyst yields an oil which is dissolved in acetone, the solution then being treated with HCl gas. The resultant dihydrochloride salt which is precipitated from solution is triturated with diethyl ether to give a low melting solid.
- 6-Aminocaproic acid is reacted with 3-benzyloxy-2-methyl-4-pyrone in an exactly analogous procedure to that described in Example 2 for the reaction of the latter compound with ⁇ -alanine to give 3-benzyloxy-1-(5′-carboxypentyl)-2-methylpyrid-4-one in 70% yield, this compound being obtained after recrystallisation from ethanol/acetone (1:1 v/v) as white crystals, m.p. 145-147°C.
- 2,3-Dihydroxypyridine (10 g) is suspended in ethylbromoacetate (40 ml) and the mixture is heated in a sealed tube for 24 hours at 140°C. The tube is then cooled in solid CO2 and opened. The contents are subjected to rotary evaporation at 50°C to yield a yellow solid. Recrystallisation of this solid from water yields 1-ethoxycarbonylmethyl-3-hydroxypyrid-2-one as white crystals (10.8 g), m.p. 141-151°C.
- 3-Benzyloxy-2-methyl-4-pyrone (5.2 g, crude) is dissolved in a mixture of ethanol (100 ml) and water (200 ml) containing sodium hydroxide (2 g), the pH of the resulting solution being about 12 to 13.
- the tri-amine, N-(2-aminoethyl)-1,3-propanediamine (0.75 g) is then added to give a reaction mixture which contains a 3.75 molar excess of the 4-pyrone to tri-amine.
- the mixture is stirred at room temperature for 6 days and is then acidified with concentrated HCl to pH 2 and rotary evaporated to give a brown solid. This solid is extracted with ethanol from which a white solid is obtained on rotary evaporation.
- 3-Benzyloxy-1-(2′-succinimyloxycarbonylethyl)-2-methylpyrid-4-one is prepared from 3-benzyloxy-1-carboxyethylpyrid-2-one by reaction with N-hydroxysuccinimide as described in Example 1, the compound being isolated in an analogous manner to that described in Example 4 for the corresponding 1-(2′-succinimyloxycarbonylethyl) compound.
- the compound is obtained in 60% yield as a solid of m.p. 144-146°C; ⁇ max (nujol) 1800, 1770, 1735, 1625, 1570 cm ⁇ 1; ⁇ (CDCl3) 2.0 (s, 3H), 2.8 (s, 4H).
- the partition coefficient K part being the ratio (concentration of compound in n-octanol)/(concentration of compound in aqueous phase) on partition between n-octanol and aqueous tris hydrochloride (20 mM, pH 7.4). is measured by spectrophotometry at 20°C for various of the compounds of the previous Examples and for their iron(III) complexes (at 10 ⁇ 4M).
- the solutions of the complexes are either produced, for compound 8, by dissolving the pre-formed complex prepared as described in Example 13, in the aqueous tris hydrochloride or, for compounds 5 and 10, by formation in the buffer in situ by the admixture of a 3:2 or 1:1 molar ratio, respectively, of the linked hydroxypyridone compound:ferric chloride, the pH thereafter being readjusted to 7.4 if necessary.
- Acid washed glassware is used throughout and, following mixing of 5 ml of the 10 ⁇ 4M aqueous solution with 5 ml n-octanol for 1 minute, the aqueous n-octanol mixture is centrifuged at 1,000 g for 30 seconds.
- the two resulting phases are separated for a concentration determination by spectrophotometry on each.
- the range 220-340 nm is used for concentration determinations whilst for the iron complexes, the range 340-640 nm is used.
- Table 2 Partition coefficients Compound Partition coefficient K part Free compound Iron complex [Fe III -(compound)3] 5 0.017 0.10 8 0.02 0.03 10 0.2 0.3
- the iron complex of 1,6-di-(3-hydroxy-2-oxypyrid-1-ylacetamido)-hexane (compound 4: described in Example 4) is prepared by either procedure (a) or procedure (b).
- N,N-[2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethyl]-2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethylamine (compound 8: described in Example 8) is reacted with ferric chloride in a 1:1 molar ratio by either procedure (a) or (b) above to give the neutral iron(III) containing the N,N-[2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethyl]-2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethylamine trivalent anion and the ferric cation in 1:1 proportion.
- This complex is obtained as wine red coloured crystals, m.p. > 300°C, ⁇ max (nujol) 1530, 1580(w), 1620(w) and 1660 cm ⁇ 1.
- the iron uptake into the serosal space of the inverted rat jejunal sac was compared for the iron complexes of two compounds described in earlier Examples.
- Rats male Sprague Dawley, 60 g
- the segments were tied at both ends and filled with Krebs Ringer buffer (0.2 ml) and incubated in Krebs Ringer buffer containing 59Fe complexes at 37°C for periods up to 1 hour (the iron complexes were prepared in situ by an analogous procedure to that described in Example 12).
- the content of the sac was counted for 59Fe and measured spectrophotometrically.
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
- This invention relates to iron complexes for use in pharmaceutical compositions.
- An adequate supply of iron to the body is an essential requirement for tissue growth in both man and animals. Although there is normally an ample amount of iron in the diet, the level of absorption of iron from food is generally low so that the supply of iron to the body can easily become critical under a variety of conditions. Iron deficiency anaemia is commonly encountered in pregnancy and may also present a problem in the newly born, particularly in certain animal species such as the pig. Moreover, in certain pathological conditions there is a maldistribution of body iron leading to a state of chronic anaemia. This is seen in chronic diseases such as rheumatoid arthritis, certain haemolytic diseases and cancer.
- Although a wide range of iron compounds is already marketed for the treatment of iron deficiency anaemia, the level of iron uptake by the body from these compounds is often quite low, necessitating the administration of relatively high dosage levels of the compound. The administration of high dose, poorly absorbed, iron complexes may cause siderosis of the gut wall and a variety of side effects such as nausea, vomiting, constipation and heavy malodorous stools. We have now found that the iron complexes of certain hydroxypyridone compounds are of particular value in the treatment of iron deficiency anaemia (in the broad sense of this term).
- Accordingly the present invention comprises an iron complex of a compound in which 2 or more rings, being a 3-hydroxypyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxypyrid-2-one, are linked.
- The hydroxypyridone rings in compounds providing iron complexes according to the present invention may be identical or may differ, either varying between the three forms of hydroxypyridone and/or, since the ring may be substituted, between differing rings of the same basic form. In general, however, there is little advantage to be gained from the presence of dissimilar rings and this can complicate the synthesis of the compound so that it is preferred that each hydroxypyridone ring in the compound is of the same one of the three forms and conveniently that each ring possesses the same substitution or lack of substitution.
- Although compounds providing iron complexes according to the present invention may contain varying numbers of rings, for example up to 10 or even 100, compounds containing 2, 3 or 4 rings are of particular interest with the 3 ring compounds being of especial use for the preparation of complexes for use in the treatment of iron deficiency anaemia.
- The iron complexes of the present invention preferably contain iron in the ferric state. Although the use of complexes containing iron in the ferrous state may be considered, such complexes tend to be less stable and are thus of less interest. The iron complexes are preferably neutral, i.e. there being an internal balance of charges between the metal cation or cations and the ligand or ligands bound covalently thereto without the necessity for the presence of a non-covalently bound ion or ions, for example a chloride ion, to achieve balance. Moreover, the use of linked hydroxpyridones containing ionisable substituent groups (or linking groups) is of less interest and it is preferred that this internal balance of charges is achieved by complexing with an iron cation or cations a compound containing the appropriate number of hydroxypyridone rings to thereby provide, by the loss of a hydroxy proton from each ring, the number of anionic groups O⁻ necessary to neutralise the charge on the cation or cations. Although such neutrality may be achieved, for example, in a complex containing a 3:2 molar proportion of an anion from a two ring compound:iron(lII), preferred neutral complexes of this type are those formed between the anion derived from a compound containing three, or a multiple of three, hydroxypyridone rings and a ferric cation, or the same multiple of ferric cations, particularly those containing a trivalent anion derived from a three ring compound and a single ferric cation. It will be appreciated, however, that the invention does not exclude the use of complexes in which the charge on the anion derived from the linked hydroxypyridone compound and that on the ferric cation or cations do not fully neutralise each other, for example owing to the presence of an ionisable linking group, so that association with a further non-covalently bound physiologically acceptable ion or ions is necessary to achieve a balance of charges, although such complexes are generally of lesser interest.
- The present invention thus particularly includes a neutral iron complex containing 1 molar proportion of iron(III) and 1 molar proportion of a compound as defined hereinbefore in which three rings are linked. The use of neutral iron complexes according to the present invention is discussed hereinafter with particular reference to such 1:1 complexes.
- The ability of both the free compound and its iron complex to permeate membranes is important in the context of the treatment of anaemia and it is also desirable for both to possess some degree of water solubility. A good indication of the physical properties of a compound and its iron complex in this respect is provided by the value of the partition coefficient (Kpart) obtained on partition between n-octanol and tris hydrochloride (20 mM, pH 7.4; tris representing 2-amino-2-hydroxymethylpropane 1,3-diol) at 20°C and expressed as the ratio (concentration of compound in organic phase)/(concentration of compound in aqueous phase). Where the compounds are to be employed in a context requiring translocation across membranes, then preferred compounds show a value of Kpart for the free compound of above 0.02 but less than 3.0, especially of above 0.2 but less than 1.0, together with a value of Kpart for the smallest neutral iron(III) complex in which there is an internal balance of charges of above 0.02 but less than 6.0, especially of above 0.2 but less than 1.0. [In a neutral complex there is an internal balance of charges between the iron cation or cations and the ligand or ligands covalently bound thereto without the necessity for the presence of a non-covalently bound ion or ions to achieve balance. In the case of two ring compounds, for example, this smallest neutral iron(III) complex will contain 3 molar proportions of the compound:2 molar proportions of iron(III) but for the preferred iron binding compounds containing three rings the complex will contain a 1:1 molar ratio of compound:iron(III).] In other contexts, such as the intraveneous use of the compounds in vivo, the value of Kpart is less critical. The comments which follow later upon preferred forms of linking groups are in part directed towards providing compounds having partition coefficients in the free and complexed state which lie in the preferred ranges indicated above.
- The hydroxypyridone rings may, for example, be substituted as discussed for the metal-free single ring compounds in UK patent applications 8308056 (published as GB 2118176A), 8407181 (published as GB 2136807A) and 8423800 (published as GB 2146990A), the equivalent European applications being A-0 093 498, A-0 094 149 and A-0 138 420, respectively, allowing for the necessity to provide a point of linkage for the various rings so that, for example, if the rings are linked through the nitrogen atoms thereof then this position of the ring may not be otherwise substituted.
- Examples of types of substitution additional to the linking groups thus include, for 3-hydroxypyrid-2-one and 3-hydroxypyrid-4-one rings, replacement of the hydrogen atom attached to the nitrogen atom by an aliphatic acyl group, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by one or, except in the case of ionisable groups, more than one substituent selected from aliphatic acyl, alkoxy, aliphatic amine, aliphatic amide, carboxy, aliphatic ester, halogen, hydroxy and sulpho groups and/or replacement of one or more of the hydrogen atoms attached to ring carbon atoms by one of said substituents, by an aliphatic hydrocarbon group, or by an aliphatic hydrocarbon group substituted by an alkoxy, aliphatic ester, halogen or hydroxy group; and for 1-hydroxypyrid-2-one rings, replacement of one or more of the hydrogen atoms attached to ring carbon atoms by a substituent selected from aliphatic acyl, aliphatic amide, aliphatic amine, carboxy, cyano, aliphatic ester, halogen, hydroxy and sulpho groups, alkoxy groups and alkoxy groups substituted by an alkoxy, aliphatic amide, aliphatic amine, aliphatic ester, halogen or hydroxy group, aliphatic hydrocarbon groups and aliphatic hydrocarbon groups substituted by an alkoxy, aliphatic ester, halogen or hydroxy group.
- Futher description of such substituents as are listed above is to be found in the earlier applications referred to hereinbefore but it may be mentioned that the ionisable substituent groups (aliphatic amine, carboxy and sulpho groups) are generally of lesser interest than the others and, indeed, substitution of the rings other than for the purpose of the linkage thereof is of much less interest than in the case of the single ring compounds. Since, as will be discussed in more detail hereinafter, the 3-hydroxypyrid-2- and -4-one rings are preferably linked through the nitrogen atoms thereof and the hydroxy group on the nitrogen atoms of the 1-hydroxypyrid-2-ones is required for iron binding, such substitution as is present is more usually limited to the carbon atoms of the ring and is preferably limited to aliphatic hydrocarbon substituent groups. Moreover, although more than one of the ring carbon atoms may be substituted, for example two of such atoms, either by the same or different substituent groups, compounds in which only one, or none, of the ring carbon atoms are substituted are preferred. Substitution may occur at various positions of the ring but, particularly when the ring carbon atoms are substituted by the larger groups, there may be an advantage in avoiding substitution on a carbon atom alpha to the
system. These systems are involved in the complexing of the compound with iron and other metals and the close proximity of one of the larger groups may lead to steric effects which inhibit complex formation. - Where reference is made to a ring being substituted by an aliphatic hydrocarbon group it will be appreciated that this term is used herein to include both acyclic and cyclic groups which may be unsaturated or especially saturated, the acyclic groups having a branched chain or especially a straight chain. Groups of from 1 to 6 carbon atoms, particularly of 1 to 4 and especially of 1 to 3 carbon atoms, are of most interest. Saturated aliphatic hydrocarbon groups are preferred, these being either cyclic groups such as the cycloalkyl groups cyclopropyl and especially cyclohexyl or, more particularly, acyclic groups such as the alkyl groups methyl, ethyl, n-propyl and isopropyl. The main interest in aliphatic hydrocarbon group substituents in the context of the present invention lies, however, in the possibility of using single ring compounds containing such a substituent on one or more carbon atoms thereof as being a more readily available starting material than the corresponding unsubstituted compound for the preparation of the multi-ring compounds. In this respect, methyl substituent groups are of particular interest and have the advantage of not being so large as to create the problems referred to above. Thus, with the 3-hydroxypyrid-4-ones, where the use of methyl substituted compounds as starting materials is of most relevance, it is likely for reasons of availability that any methyl substituent will in fact be located at the 2- or 6-position.
- Preferred ring systems present in the compounds providing iron complexes of the present invention are shown below, the free valency in each case indicating the preferred point of attachment of the linking group between one ring and another (it will be appreciated that the 1-hydroxypyrid-2-ones are tautomeric compounds, being alteratively named as 2-hydroxypyridine-1-oxides).
The hydroxypyridone rings may be linked through various types of linking group, the important feature of the compounds being the rings contained therein and the nature of the linking groups therefore being of lesser importance. Linking groups which are either wholly of a hydrocarbon nature or which additionally contain one or more of the same or different groups selected from -O-, -S-, -NH-,
-CONH- and -CON〈 are of value by virtue of the ease of synthesis and non-interference in the metal complexing action of the compounds. - For reasons of simplification of the description only, the preparation of compounds according to the present invention will be further described with particular reference to the preparation of two ring and three ring compounds.
- Examples of suitable linking hydrocarbon linking groups are a benzene group substituted by two or more methylene groups, and various aliphatic hydrocarbon groups. The latter may conveniently contain between 6 and 18 or 24 carbon atoms, especially between 6 or 8 and 12 carbon atoms, and when used in two ring compounds, where they are particularly useful, are preferably straight chain alkylene groups, although when used as a single linking group in compounds containing more than two rings they must necessarily be branched. Specific examples of such straight chain alkylene groups are groups -(CH₂)n- in which n is an integer from 6 to 12, for example 8, 9 or 10.
- Alternative linking groups of especial interest are groups corresponding to a hydrocarbon group in which one or more carbon atoms are replaced by a nitrogen atom and/or in which one or more pairs of adjacent carbon atoms are replaced by a -CONH- group. Such groups are preferably of similar overall size (i.e. contain a similar total number of atoms in the backbone or chain thereof) to the hydrocarbon groups described above. Certain of such groups are of particular interest in the context of divalent linking groups for use in two ring compounds. These divalent groups may conveniently correspond to a straight chain alkylene group in which one carbon atom is replaced by a -NH- group and/or in which two pairs of adjacent carbon atoms are replaced by a -CONH- group. They will often contain one imino group in a substantially central position in the chain and/or one amido group located adjacent to each end of the chain, the carbonyl group thereof often being bonded to the terminal or penultimate carbon atom of the chain. Specific examples of such linking groups are
-(CH₂)a-NH-(CH₂)b- (1)
-(CH₂)c-CONH-(CH₂)d-NHCO-(CH₂)c- (2)
-(CH₂)c-CONH-(CH₂)e-NH-(CH₂)f-NHCO-(CH₂)c- (3)
wherein a and b are each an integer from 2 to 6, for example 2 to 5, and especially a = 2, b = 3, or a = 3, b = 4, or a = 5, b = 5; c is an integer from 1 to 5, especially 1 to 3, for example 1 or 2, and d is an integer from 2 to 8, for example, c = 1 and d = 6, or c = 2 and d = 2 or 4; and e and f are each an integer from 2 to 4, for example c = 1, e = 2 and f = 3, or c = 2, e = 2 and f = 2 (values of d, e and f of 1 lead to linking groups containing the somewhat unstable
grouping). As regards the overall size of these linking groups, in the case of (2) it is preferred that - Trivalent linking groups of use in the present invention in the preparation of three ring compounds may include both the hydrocarbon and modified hydrocarbon types referred to hereinbefore. They are often similar to the divalent linking groups described above, modified so as to have three parts each terminating in a free valency arranged about the centre of the linking group instead of two. Groups of especial interest are a benzene group which is 1,3,5-substituted by three methylene groups and tripod groups consisting of a nitrogen atom substituted by three alkylene groups, for example straight chain groups of 1 to 6 carbon atoms and particularly 4 or 5 carbon atoms, or similar substituted benzene groups or tripod groups in which the methylene or alkylene groups are terminally substituted by a group -NHCO-(CH₂)c- wherein c is as defined hereinbefore. In this latter case involving further terminal substitution, the three alkylene groups attached to the nitrogen atom of the tripod group may generally be somewhat shorter than previously indicated, preferably being straight chain and conveniently being of 1 to 4 carbon atoms, particularly of 2 or 3 carbon atoms when c is 1, for example of 2 carbon atoms each or of 2, 3 and 3 carbon atoms, respectively. Also of some considerable interest are trivalent groups similar to those divalent groups described above corresponding to an alkylene group in which one carbon atom is replaced by a -NH- group and also two pairs of carbon atoms are replaced by a -CONH- group. In this case, the trivalent group may be viewed as corresponding to a branched, trivalent hydrocarbon group in which a 〉̶CH group is replaced by 〉̶N and three pairs of adjacent carbon atoms are replaced by a -CONH- group. Alternatively, they may be viewed in a closer analogy to the divalent groups as corresponding to a straight chain alkylene group in which a -CH₂- group is replaced by a 〉N-CO(CH₂)g- group wherein g is an integer from 1 to 3, especially being 1, and two pairs of carbon atoms are replaced by a -CONH- group. Again, these groups will often contain a nitrogen atom in a substantially central position in the chain and/or one amido group located adjacent to each end of the chain, the carbonyl group thereof often being bonded to the terminal or penultimate carbon atom of the chain. Specific examples of such linking groups are
wherein c, e, f and g are as defined above and h is an integer from 1 to 4, preferably 2 to 4, and especially, for (4), c = 1, e = 2, f = 3 and g = 1, or c = 1, e = 3, f = 4 and g = 1, or c = 1, e = 3, f = 4 and g = 2, and for (5), c = 1 and e = f = h = 2 or c = 2 and e = f = h = 2. As regards the overall size of these linking groups, in the case of (4) it is preferred that - As regards tetravalent linking groups these may with particular convenience contain a fully branched carbon atom
which may be attached to four groups which are either wholly of a hydrocarbon nature or which additionally contain other groups such as those described hereinbefore. An example of this type of linking group has the form
where each of a, a′, b and b′ is an integer from 1 to 6, for example the same integer, a particular linking group having each of a, a′, b and b′ = 1. - By way of further guidance in the selection of suitable linking groups it may be stated that, for particularly preferred compounds, in the case of the 3-hydroxypyrid-2-ones the nitrogen atoms of the rings may conveniently be separated by 6 to 12, preferably 8 to 10 atoms, whilst with the 3-hydroxypyrid-4-ones a convenient range is 8 to 16, preferably 9 to 11 or 12 atoms. The situation with the 1-hydroxypyrid-2-ones will depend on the position of attachment of the linking groups but, in the preferred case of linking of the rings through the 4-position, the situation is analogous to that of the 3-hydroxypyrid-4-ones.
- The compounds providing iron complexes according to the present invention may be synthesised using various different approaches. In the case of the 3-hydroxypyridones, as mentioned hereinbefore, linkage is usually effected through the nitrogen atom of the ring. One approach, which is particularly applicable to the 3-hydroxypyrid-2-ones, involves reaction of the 3-hydroxypyridone, in a suitable proportion, with a reagent providing the linking group which contains the appropriate number of functional groups capable of reaction with the -NH- group of the pyridone. This procedure is of particular interest for the preparation of two ring compounds and suitable functional groups include the iodo group. Routes to C-substituted 3-hydroxypyridones are discussed in the UK patent applications 8308056 and 8407181 and their European equivalents referred to hereinbefore but, as indicated before, the more readily available compounds in which the carbon atoms of the ring are unsubstituted or substituted only by an aliphatic hydrocarbon group are of greater interest as starting materials.
- A second approach involves reaction of a 3-hydroxypyridone which is N-substituted by a substituent containing a suitable first functional group with a reagent containing suitable second functional groups for reaction with said first group, the linking group deriving from both the N-substituent and the reagent. The procedure is of particular application for both the 3-hydrox-pyrid-2- and -4-ones in the preparation of two ring and three ring compounds, and suitable functional groups include a combination of a carboxy group and an amino group, either one of which may be attached to the 3-hydroxypyridone and the other of which to the reagent. Thus, the hydroxypyridone may, for example, be N-substituted by a group -(CH₂)i-CO₂H or -(CH₂)i-NH₂ wherein i is an integer from 1 to 5, for example 1, 2 or 3. The reagent in the former case, which is the preferred one, may be a di- or tri-amine, etc., and in the later case a di- or tri-carboxylic acid, although it will be appreciated that it is usual, whether the carboxy group is on the hydroxypyridone or the reagent, to activate it before reaction. Such activation may, for example, involve the use of an activated ester such as the p-nitrophenyl or 1-succinimyl ester and it will be usual to protect the ring hydroxy group, for example by benzylation, to prevent reaction thereof with the activated ester group or other form of activated carboxy group.
- Yet a third approach may be used in the case of the 3-hydroxypyrid-4-ones where it is possible to react a di- or tri-amine, with a protected 3-hydroxy-4-pyrone, for example a 3-benzyloxy-4-pyrone, to replace the ring oxygen atom by a nitrogen atom of the reagent and thus effect linkage of two, three or more rings. Certain 3-hydroxy-4-pyrones, such as the unsubstituted compound and the 2-methyl substituted compound, maltol, are available commercially. Other readily available compounds include the 6-methyl substituted compound, isomaltol, and other 2-alkyl substituted compounds whose synthesis is described in US application serial number 310,141 (series of 1960).
- A specific example of such a first approach as described above involves the use of a reagent I-(CH₂)n-I, wherein n is as defined hereinbefore, and the reagent C-( CH₂Br)₄ to prepare compounds containing two or four linked 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one rings, respectively, for example the rings (I) and (III) as shown hereinbefore. Specific examples of the second approach utilise a reagent H₂N-(CH₂)d-NH₂, H₂N-(CH₂)e-NH-(CH₂)f-NH₂,
where d is as defined hereinbefore, for example being 2, 4, 6 or 8; e and f are as defined hereinbefore, for example being 2 and 3 respectively or each being 2; and i, j and k are each an integer from 1 to 4, for example each being 2 or being 2, 3 and 3 respectively. Such reagents are used to prepare compounds containing two or three linked rings by reaction with a 3-hydroxypyrid-2- or -4-one, for example a compound corresponding to one of the formulae (I) to (IV) as shown hereinbefore, with an N-substituent, for example a group -CH₂CO₂H, -(CH₂)₂-CO₂H, -(CH₂)₃-CO₂H, -(CH₂)₄-CO₂H or -(CH₂)₅-CO₂H in activated form. The third approach may be used with a reagent similar to those described for use in the second approach, for example a reagent H₂N-(CH₂)a-NH-(CH₂)b-NH₂ where a and b are as defined hereinbefore, or H₂N-(CH₂)n-NH₂ where n is as defined hereinbefore, for example being 8 or 9, or more conveniently with a reagent corresponding to a linking group (2), (3) or (4) as described above having c = 1 and terminating at the free valencies in an amino group, such reagents being used to prepare compound containing two or three linked rings by reaction with 3-hydroxy-4-pyrones having a protected hydroxy group, for example the O-benzylated pyrones corresponding to the pyridones (II), (III) and (IV), followed by deprotection. (Such specific reagents may also be used in the second approach, although less conveniently, as an alternative to those described above.) - Consideration of these various approaches will show that, in some instances, certain of the linking groups described above are preferred in the case of certain types of hydroxypyridone and also that, in some instances, the same type of linking group may be produced by different approaches so that, for example, an amido function in the linking group may be present in the reagent used to form that group or may be produced by the reaction of an amine group and an activated ester group, one of which is attached to the reagent and the other to the hydroxypyridone ring. The selection of a synthetic route for the preparation of a particular compound will depend on various factors, including the relative availability of suitable intermediates.
- It will be appreciated that the present invention extends to iron complexes of the various compounds, per se, obtainable by the specific examples of these three approaches described above for use in connection with the 3-hydroxypyridones.
- In the case of the 1-hydroxypyrid-2-ones it is not possible to effect linkage of the rings through the nitrogen atoms thereof and linkage is therefore effected at one of the carbon atoms of the ring. The preferred approach to such linking is analogous to the second approach described above for the linking of 3-hydroxypyrid-2-and -4-ones in that it involves the use of a 1-hydroxypyrid-2-one having a substituent containing a suitable functional group, for example at the 4-position of the ring, which is reacted with a reagent containing suitable functional groups for reaction therewith. The previous discussion in relation to the second approach used with 3-hydroxypyrid-2- and -4-ones therefore applies also in the present case, with the modification that groups such as -(CH₂)i-CO₂H or -(CH₂)i-NH₂, wherein is as defined hereinbefore, are more usually attached to a ring carbon atom of a 1-hydroxypyrid-2-one through another group, particularly an -O-group, in view of the greater ease of synthesising aminoalkoxy and carboxyalkoxy substituted 1-hydroxypyrid-2-ones as compared with the aminoalkyl and carboxyalkyl substituted compounds. The synthesis of such substituted 1-hydroxypyrid-2-ones is discussed in detail in UK patent applicatin 8423800 and its European equivalent referred to hereinbefore but it may conveniently be achieved using a compound such as 2-chloro-4-nitropyridine-1-oxide for example, which may be subjected to nucleophilic substitution to replace the nitro group by a substituted alkoxy group which corresponds to or is convertible to that required, the chloro group then being converted to a hydroxy group by basic hydrolysis. It will be appreciated that the present invention extends to the various compounds, per se, obtainable using the specific reagents referred to above in connection with the second approach for the linking of 3-hydroxypyrid-2- and -4-ones when used in conjuction with a 1-hydroxypyrid-2-one which is C-substituted by a group -O-(CH₂)i-CO₂H or -O-(CH₂)i-NH₂, wherein i is as defined hereinbefore and is preferably greater than 1 in the case of the latter type of group. The carboxy group will be in activated form in the former case, and both types of group may conveniently be substituted at the 4-position of the 1-hydroxypyrid-2-one.
- The synthesis of compounds providing iron complexes according to the present invention and of various reagents providing linking groups between the hydroxypyridone rings is illustrated hereinafter in the Examples. Compounds useful as reagents in the preparation of linking groups containing amide functions may readily be prepared from suitable amine precursors by reaction with the appropriate acylating agent, conveniently in the form of an activated ester. Thus, for example, the amine N-(2-aminoethyl)-1,3-propanediamine used in Example 6 may be reacted, as described in the footnote (1)(A) and (B) to that Example, with a glycine derivative in which the carboxy group is in activated ester form and the amino group is protected, for example as N-benzylglycine p-nitrophenyl ester, to provide, after removal of the N-protecting group, the compound H₂N-CH₂CONH-(CH₂)₂-NH-(CH₂)₃-NHCOCH₂-NH₂ or the compound H₂N-CH₂CONH-(CH₂)₂-N(COCH₂-NH₂)-(CH₂)₃-NHCOCO₂-NH₂, depending on the conditions used. Thus, in ethyl acetate and like solvents the former compound will precipitate from the reaction mixture and the latter compound is not formed even in the presence of a three, rather than two, molar proportion of the glycine derivative. However, in a more polar solvent, such as dimethylformamide, a three molar proportion will lead to the formation of the latter compound. The former compound may be used as such in the preparation of two ring compounds or, alternatively, may be reacted in a solvent such as dimethylformamide with another amino acid. Thus, reaction with a suitable β-alanine derivative, for example, will lead to the formation of the compound H₂N-CH₂CONH-(CH₂)₂-N(COCH₂CH₂-NH₂)-(CH₂)₃-NHCOCH₂-NH₂.
- It will be appreciated that the procedures which have been described and illustrated herein with particular reference to the production of two ring and three ring compounds may be applied with appropriate modification for the production of compounds containing more rings than this. Moreover, it will be appreciated that the routes described are not the only routes available to the compounds providing iron complexes of the present invention and that various alternatives may be used as will be apparent to those skilled in the art.
- The iron complexes are conveniently prepared by the reaction of the linked hydroxypyridone compound and iron ions, the latter conveniently being derived from an iron salt, particularly a ferric halide and especially ferric chloride. The reaction is conveniently effected in a suitable mutual solvent and water may often be used for this purpose. If desired, however, an aqueous/organic solvent mixture may be used or an organic solvent, for example ethanol, methanol, chloroform and mixtures of these solvents together and/or with water where appropriate. In particular, methanol or especially ethanol may be used as the solvent where it is desired to effect the separation of at least a major part of a by-product such as sodium chloride by precipitation whilst the iron complex is retained in solution. Alternative procedures may, however, be used and will be apparent to those skilled in the art.
- It will be appreciated that the nature of the iron complex obtained by the reaction of a linked hydroxypyridone compound and iron ions will depend both on the proportion of these two reactants and upon the pH of the reaction medium. Thus, for the preparation of a 1:1 ferric complex, for example, the linked three ring hydroxypyridone compound and the ferric salt are conveniently mixed in solution in a 1:1 molar proportion and the pH adjusted to a value in the range of 6 to 9, for example 7 or 8. Adjustment of the pH may conveniently be effected by the addition either of sodium carbonate or of a hydroxide base such as sodium or ammonium hydroxide, the use of a hydroxide base being of particular interest when preparing the iron complexes in batches of 20 g or more. When using a hydroxide base, the reaction may conveniently be carried out in a medium containing water as the solvent, for example in water or an ethanol:water mixture, and the pH adjusted by the addition of a 2 molar aqueous solution of the base. It will be appreciated that the presence of water in the reaction mixture will lead to the retention of a by-product in the iron complex on evaporation of the solvent (a chloride where the iron salt is ferric chloride). However, this can be removed, if desired, by procedures such as crystallisation from a suitable solvent system or sublimation in the particular case of ammonium chloride.
- Reaction to form the iron complex is generally rapid and will usually have proceeded substantially to completion after 5 minutes at about 20°C, although a longer reaction time may be used if necessary. Following separation of any precipitated by-product, such as sodium chloride in the case of certain solvent systems, the reaction mixture may conveniently be evaporated on a rotary evaporator or freeze dried to yield the solid iron complex. This may, if desired, be crystallised from a suitable solvent, for example water, an alcohol such as ethanol, or a solvent mixture, including mixtures containing an ether. The present invention thus further includes a process for the preparation of an iron complex of a linked hydroxypyridone compound as defined hereinbefore which comprises reacting said compound with iron ions and isolating the resultant complex.
- Whilst for some uses it may be appropriate to prepare the iron complex in substantially pure form, i.e. substantially free from by-products of manufacture, in other cases, for example with a solid oral formulation as described hereinafter, the presence of by-products such as sodium chloride may be quite acceptable. In general, however, the neutral 1:1 [linked hydroxypyridone compound: iron(III)] complex is of particular interest in a form free from by-products which are complexes containing different proportions of hydroxypyridone and iron. As indicated hereinafter, it may be advantageous under some circumstances for the iron complex to be used in admixture with the metal-free linked hydroxypyridone compound and, if desired, such a mixture may be obtained directly by reacting a molar proportion of the compound and iron ions of greater than 1:1.
- The complexes may be formulated for use as pharmaceuticals for veterinary, for example in an avian or especially a mammalian context, or particularly human use by a variety of methods. For instance, they may be applied as an aqueous, oily or emulsified composition incorporating a liquid diluent which most usually will be employed for parenteral administration and therefore will be sterile and pyrogen free. Although compositions incorporating a liquid diluent may also be used for oral administration, it is preferred to use compositions incorporating a solid carrier, for example a conventional solid carrier material such as starch, lactose, dextrin or magnesium stearate, the oral composition then conveniently being of a formed type, for example as tablets capsules, (including spansules), etc.
- Other forms of administration than by injection or through the oral route may also be considered in both human and veterinary contexts, for example other forms known in the art such as the use of suppositories or pessaries, particularly for human administration.
- The iron complexes may especially be applied by parenteral administration, particularly in the context of animal treatment. The problems of iron deficiency anaemia in newly born pigs arise primarily during the first three weeks or so of their life when a very rapid weight gain takes place. The iron complexes of the present invention may be used to treat piglets directly by a parenteral route, for example intramuscular, or oral, for example as a liquid preparation "injected into the mouth". However, an alternative approach is to enhance the iron content of the milk on which the piglets are feeding by treating the mother pig using oral or parenteral administration, for example an injectable slow release preparation (such an approach may also be of interest in a human context). When it is applicable to feed piglets on foodstuffs other than the milk of the mother pig, it may also be possible to effect the pharmaceutical administration of the iron complex in this other foodstuff.
- Compositions may be formulated in unit dosage form, i.e. in the form of discrete portions each comprising a unit dose, or a multiple or sub-multiple of a unit dose. Whilst the dosage of active compound given will depend on various factors, including the particular compound which is employed in the composition, it may be stated by way of guidance, however, that maintenance of the amount of iron present in the human body at a satisfactory level will often be achieved using a daily dosage, in terms of the iron content of the compound, which lies in a range from about 0.1 to 100 mg and often in a range from 0.5 to 10 mg, for example 1 or 2 mg, veterinary doses being on a similar g/Kg body weight ratio. However, it will be appreciated that it may be appropriate under certain circumstances to give daily dosages either below or above these levels. In general, the aim should be to provide the amount of iron required by the patient without administering any undue excess and the properties of the pharmaceutical compositions according to the present invention are particularly suited to the achievement of this aim. Where desired, an iron complex of more than one linked hydroxypyridone compound as described above may be present in the pharmaceutical composition or indeed other active compounds may be included in the composition, for example compounds having the ability to facilitate the treatment of anaemia, such as folic acid. Another additional component which may be included in the composition, if desired, is a source of zinc. Iron compounds used in the treatment of iron deficiency anaemia can inhibit the mechanism of zinc uptake in the body and this can cause serious side effects in the foetus when treating anaemia in a pregnant female. It is believed, however, that the iron complexes of the present invention have a further advantage in that they either do not have this effect or exhibit the effect at a lower level than the compounds at present used in the treatment of anaemia. Accordingly, it may often be the case that the level of zinc providing compound added to the composition may not require to be high or, with preferred formulations of the iron complexes, may be dispensed with altogether.
- We have found that the iron complexes described herein are of value in the treatment of iron deficiency anaemia both in humans and also in a veterinary context, particularly for the treatment of various mammalian species and especially pigs. The complexes will partition into n-octanol indicating that they are able to permeate biological membranes, this property being confirmed in practice by tests of the ability of the ⁵⁹Fe labelled iron complexes to permeate erythrocytes. The ability of the compounds in this respect will depend on the nature of the substituent(s) present therein and the reflection of this ability in the Kpart values of various compounds has been referred to hereinbefore. Once present in the bloodstream, the complexes will donate iron to transferrin, a position of equilibrium being set up between the complexes and transferrin. It is because of the existence of this equilibrium that the corresponding metal-free linked hydroxypyridone compound may equally be used in the treatment of iron overload, although certain of these compounds may be of particular value for use in the free state for iron removal and others may be of particular value for use as iron complexes for iron supply.
- Certain aspects of their formulation may enhance the activity of the complexes in particular contexts. Thus, the neutral 1:1 ferric complexes are of particular value as being stable over a wide pH range from about 4 or 5 up to 10 and even at the pH values of less than 4 prevailing in the stomach free iron should not be liberated. Thus, it has been observed that, even at pH 0.5, the iron of such a 1:1 complex is still bound although not necessarily by all six of the original covalent bonds. Moreover, when the complex is cleared from the stomach and reaches the small intestine any internal dissociation of the bonds within the complex should be reversed under the alkaline conditions prevailing therein. Protection of the iron complexes from the acidic conditions of the stomach should not therefore be necesary from the point of view of preventing the liberation of iron from the complex. It is possible with some forms of linking group, however, that breakdown of the group may occur under the acidic conditions prevailing in the stomach, for example by cleavage of an amide group. In such circumstances, the use of a method of formulation which avoids or reduces exposure of the iron complex to the acidic conditions of the stomach can be of value. Such an approach may involve various types of controlled release system, ranging from one, which may for example be based on a polymer, which simply provides a delayed release of the complex with time, through a system which is resistant to dissociation under acidic conditions, for example by the use of buffering, to a system which and is biased towards release under conditions such as prevail in the small intestine, for example a pH sensitive system which is stabilised towards a pH of 1 to 3 such as prevails in the stomach but not one of 7 to 9 such as prevails in the small intestine. Since the pH of the stomach is higher after a meal, it may be advantageous, whatever method of formulation is used, to administer the iron complexes at such a time.
- A particularly convenient approach to a controlled release composition involves encapsulating the iron complex by a material which is resistant to dissociation in the stomach but which is adapted towards dissociation in the small intestine (or possibly, if the dissociation is slow, in the large intestine). Such encapsulation may be achieved with liposomes, phospholipids generally being resistant to dissociation under acidic conditions. The liposomally entrapped 1:1 iron(III) complexes can therefore survive the acid environment of the stomach without dissociation. On entry into the small intestine, the pancreatic enzymes rapidly destroy the phospholipid-dependent structure of the liposomes thereby releasing the 1:1 complex. Liposome disruption is further facilitated by the presence of bile salts. However, it is usually more convenient to effect the encapsulation, including micro-encapsulation, by the use of a solid composition of a pH sensitive nature.
- The preparation of solid compositions adapted to resist dissociation under acidic conditions but adapted towards dissociation under non-acidic conditions is well known in the art and most often involves the use of enteric coating, whereby tablets, capsules, etc, or the individual particles or granules contained therein, are coated with a suitable material. Such procedures are described, for example, in the article entitled "Production of enteric coated capsules" by Jones in Manufacturing Chemist and Aerosol News, May 1970, and in such standard reference books as "Pharmaceutical Dosage Forms", Volume III by Liebermann and Lackmann (published by Marcel Decker). One particular method of encapsulation involves the use of gelatine capsules coated with a cellulose acetate phthalate/diethylphthalate layer. This coating protects the gelatin capsule from the action of water under the acid conditions of the stomach where the coating is protonated and therefore stable. The coating is however destabilised under the neutral/alkaline conditions of the intestine where it is not protonated, thereby allowing water to act on the gelatin. Once released in the intestine the rate of permeation of the intestine wall by the water soluble 1:1 iron(III) complex is relatively constant irrespective of the position within the intestine, i.e. whether in the jejunum, ileum or large intestine. Other examples of methods of formulation which may be used include the use of polymeric hydrogel formulations which do not actually encapsulate the iron complex but which are resistant to dissociation under acidic conditions.
- Another aspect of the formulation of the iron complexes to confer certain particular advantages is the use of a metal-free linked hydroxypyridone compound in admixture with its iron complex. Thus, as mentioned hereinbefore, in certain pathological conditions there may be an excess of iron deposited at certain sites even though the patient exhibits an overall anaemia. In patients having such conditions the use of such a mixture has the advantage that the iron complex will remedy the overall anaemia whilst the free linked hydroxypyridone compound will act to remove iron from pathological to physiological sites. Moreover, there may be an advantage in formulating the iron complex of one compound as described herein with another one of such compounds in the metal-free form. Thus, it is preferable for the linked hydroxypyridone compound present in an iron donor to be rapidly metabolized so as to effect its removal from the system once it has given up its iron at an appropriate site in the system, whilst it is preferable for a linked hydroxypyridone compound being used as an iron remover not to be rapidly metabolized so that it remains in the system, taking up iron, for an extended period. For this reason the use of different linked hydroxypyridone compounds in the free form and as the iron complex has certain advantages. Moreover, different compounds may, for other reasons, function more efficiently either in the free form as an iron remover or in complex form as an iron donor. If desired, the free compound may alternatively be used in the form of a salt formed with the anion produced by the loss of a hydroxy proton and containing a physiologically acceptable cation. As an alternative to combination with a different metal-free linked hydroxypyridone compound of the same type, the iron complex may be used in combination with another iron chelating agent.
- When using such a mixture of an iron complex of a linked hydroxypyridone compound and a metal-free linked hydroxypyridone compound, the daily dosage of the iron complex may be as previously described and the daily dosage of the free compound may also be that described in relation to the use of such compounds in iron overload conditions.
- In addition to the pharmaceutical uses of the iron complexes discussed above they are also of potential interest as a source of iron in various other contexts including in cell and bacterial growth, in plant growth, as a colouring agent and in the control of iron transport across membranes.
- The invention is illustrated by the following Examples of which Examples 12, 13 and 14 relate to the preparation and use of the iron complexes, Example 11 relates to partition data on both the iron complexes of linked 3-hydroxypyridones and the corresponding metal-free linked 3-hydroxypyridones, whilst Examples 1 to 10 relate to the preparation of metal-free linked hydroxypyridones of use in the preparation of iron complexes according to the present invention. These Examples 1 to 10 describe the preparation of various compounds of the form
wherein R, R′ and R˝ each represent a substituted or unsubstituted 3-hydroxypyrid-2-one, 3-hydroxypyrid-4-one or 1-hydroxypyrid-2-one ring, n represents 0 or an integer 1, 2, 3, 4 etc. (no rings R˝ being present when n is 0) and L represents a linking group. - The exemplified compounds contain two or three 3-hydroxypyrid-2-one or 3-hydroxy-2-methylpyrid-4-one rings joined by a variety of linking groups. For greater ease of reference the different compounds described in the Examples are illustrated in Table 1, the numbering of the compounds corresponding to that of the Examples. It will be appreciated that further compounds may be produced by using in the procedures of Examples 2, 3, 7 and 9 the corresponding 3-hydroxypyrid-2-one reagent with the same linking group reagents as described in these Examples and in the procedures of Examples 4, 5, 8 and 10 the corresponding 3-hydroxy-2-methylpyrid-4-one reagent with the same linking reagents as described in these Examples. Such further specific compounds comprising 3-hydroxypyrid-2-one rings with a linking group such as is present in compounds 2, 3, 7 and 9 and 3-hydroxy-2-methylpyrid-4-one rings with a linking group such as is present in compounds 4, 5, 8 and 10 are thus also individually included within the scope of the present invention.
- It will also be noted that, as discussed hereinbefore in relation to the preparation of amine reactants, a change in the nature of the solvent used can produce a different reaction product. Thus, in Example 7 where methylene chloride is used, the secondary amine group in the reactant does not react with the active ester, while in Example 8 where the more polar dimethylformamide is used as the solvent, the secondary amine group in the reactant does react with the active ester. It will be appreciated therefore that different products containing three rather than two rings, or vice versa, may be obtained in the procedures of Examples 7, 8, 9 and 10 by using different reaction conditions.
- 3-Hydroxy-2-methyl-4-pyrone (22.2 g) in methanol (225 ml) is added to aqueous sodium hydroxide (25 ml H₂O containing 7.5 g NaOH). Benzyl chloride (25.5 g) is added and the mixture is refluxed for 6 hours and is then allowed to cool overnight. The bulk of the methanol is removed under vacuum and the residue is treated with water (50 ml). The mixture is extracted into dichloromethane (3 x 25 ml). The extracts are combined, washed with 5% w/v NaOH (2 x 25 ml), then water (2 x 25 ml) and dried over magnesium sulphate. Evaporation of the solvent gives crude 3-benzyloxy-2-methyl-4-pyrone or "benzyl maltol" (35 g, 92%) which is purified by distillation in nitrogen under reduced pressure to yield a colourless oil (28 g) of b.p. 148°C/0.2 mm.
- 3-Benzyloxy-2-methyl-4-pyrone (0.066 moles) and 1,8-diaminooctane (0.022 moles) are mixed in 2:1 v/v aqueous methanol (300 ml), solid sodium hydroxide (2 g) is added, and the mixture is heated on a steam bath for 5 hours. The mixture is allowed to cool and an aliquot is taken, acidified to pH 2 with concentrated hydrochloric acid and the solvent removed on the rotary evaporator to give a solid residue. This residue is checked for completion of the reaction through its n.m.r. spectrum, the presence of protons exchangeable at ca δ = 8.3 (d₆DMSO) showing that the reaction is not complete. If this is the case, refluxing is continued until the solid obtained from an aliquot shows no such protons. On complete reaction being found to have occurred, the mixture is cooled and acidified to pH 2 with concentrated hydrochloric acid, any precipitate formed at this stage being dissolved by the addition of methanol to the mixture. Palladium/carbon catalyst is then added and the solution is hydrogenated at room temperature and atmospheric pressure in order to effect debenzylation. The catalyst is removed by filtration and the solvent by rotary evaporation, the resulting solid then being recrystallised from water to give the title compound(1) in 40% yield as a white solid of m.p. 297-300° dec; γmax (nujol) 1340 and 1620 cm⁻¹; δ(d₆DMSO/D₂O), 1.5 (m, 12H), 2.5 (s, 6H), 4.3 (m, 4H), 7.1 (d, 2H) and 8.1 (d, 2H); m/e 360.
(1)In a variation of the above procedure, 3-benzyloxy-2-methyl-4-pyrone is reacted with 1,9-diaminononane to give compound 1A, 1,9-di-(3-hydroxy-2-methyl-4-oxopyrid-1-yl)-nonane in 45% yield as a white solid of m.p. 275-280°C dec; γmax (nujol) 1420 and 1620 cm⁻¹; δ(d₆DMSO), 1.2-2.1 (m, 14H), 2.7 (s, 6H), 4.4 (m, 4H), 7.3 (d, 2H) and 8.3 (d, 2H); m/e 374. - β-Alanine (5 g) in water (50 ml) is added to 3-benzyloxy-2-methyl-4-pyrone (10 g) in 95% ethanol (100 ml) and sodium hydroxide (4 g) in water (50 ml) is then slowly added to the reaction mixture until a pH of 13 is obtained. The solution is refluxed for 15 minutes during which time the colour changes from yellow to amber. After cooling, the solution is acidified to pH 2.5 with concentrated HCl (about 2 ml) and is then rotary evaporated at 50°C. The resulting oil is subjected to a methylene chloride/water extraction. The solid which remains is triturated with acetone and recrystallised from water to give 3-benzyloxy-1-(2′-carboxyethyl)-2-methylpyrid-4-one, m.p. 81-83°C.
- The 3-benzyloxy-1-(2′-carboxyethyl)-2-methylpyrid-4-one (1 g) and N-hydroxysuccinamide (0.45 g) are dissolved in methylene chloride (7 ml) and dicyclohexyl carbodiimide (0.8 g) in methylene chloride (3 ml) is added slowly at 0°C with stirring. After 15 minutes the precipitate which has formed is separated by filtration and the filtrate is added to a solution of 1,8-diaminooctane (0.2 g) in methylene chloride (5 ml). The reaction mixture is then rotary evaporated to yield an oil which is dissolved in ethanol (30 ml) and hydrogenated over a palladium/charcoal catalyst. Evaporation of the solution remaining after separation of the catalyst yields an oil which is dissolved in acetone, the solution then being treated with HCl gas. The resultant dihydrochloride salt which is precipitated from solution is triturated with diethyl ether to give a low melting solid. This solid is further purified by chromatography on Sephadex G-10 to yield the title compound as the dihydrochloride salt in approximately 50% yield, δ(d₆DMSO) 1.1 (m, 8H), 1.9 (m, 4H), 2.5 (s, 6H), 2.7 (m, 4H), 2.9 (m, 4H), 4.5 (t, 4H). 7.3 (d, 2H), 8.1 (d, 2H).
- 6-Aminocaproic acid is reacted with 3-benzyloxy-2-methyl-4-pyrone in an exactly analogous procedure to that described in Example 2 for the reaction of the latter compound with β-alanine to give 3-benzyloxy-1-(5′-carboxypentyl)-2-methylpyrid-4-one in 70% yield, this compound being obtained after recrystallisation from ethanol/acetone (1:1 v/v) as white crystals, m.p. 145-147°C.
- 3-Benzyloxy-1-(5′-carboxypentyl)-2-methylpyrid-4-one (1 g) and N-hydroxysuccinimide (0.4 g) are dissolved in methylene chloride (20 ml) and dicyclohexylcarbodiimide (0.7 g) in methylene chloride (5 ml) is added slowly at 0°C with stirring. After 20 minutes the resulting precipitate is separated by filtration and the filtrate is treated with stirring with a solution of diaminoethane (0.092 g) in methylene chloride (1 ml). A flocculant precipitate is formed which is filtered to give a very hygroscopic solid which rapidly forms an oil. This oil is dissolved in 95% ethanol and hydrogenated over a platinum/charcoal catalyst. The solution remaining after separation of the catalyst is rotary evaporated to yield an oil which is triturated with acetone and then with diethyl ether to yield the title compound as a hygroscopic buff solid, δ(d₆DMSO) 1.0-1.7 (m, 12H), 2.0 (s, 6H), 2.2 (m, 4H). 3.0 (m, 4H), 3.8 (m, 4H), 6.0 (d, 2H), 7.4 (d, 2H), 7.7 (m, 2H).
(1) In a variation of this procedure the compounds 3-benzyloxy-1-(3′-carboxypropyl)-2-methylpyrid-4-one and 3-benzyloxy-1-carboxymethyl-2-methylpyrid-4-one are prepared in an analogous manner using 4-aminobutyric acid and glycine, respectively, then converted to the active ester and reacted with diaminoethane to give (A) 1,2-di-[4-(3-hydroxy-2-methyl-4-oxopyrid-1-yl)-butanamido]-ethane and (B) 1,2-di-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-ethane, respectively. - 2,3-Dihydroxypyridine (10 g) is suspended in ethylbromoacetate (40 ml) and the mixture is heated in a sealed tube for 24 hours at 140°C. The tube is then cooled in solid CO₂ and opened. The contents are subjected to rotary evaporation at 50°C to yield a yellow solid. Recrystallisation of this solid from water yields 1-ethoxycarbonylmethyl-3-hydroxypyrid-2-one as white crystals (10.8 g), m.p. 141-151°C.
- 1-Ethoxycarbonylmethyl-3-hydroxypyrid-2-one (10 g) is dissolved in methanol/water (9:1 v/v) (400 ml). To this solution is added benzyl chloride (3 molar excess) and NaOH until the pH is above 12. The mixture is then refluxed for six hours to give a clear orange solution. The methanol is removed by rotary evaporation and the aqueous solution is extracted with dichloromethane to remove excess benzyl chloride. The aqueous phase is diluted slightly by adding extra water and then acidified to pH 2 using concentrated hydrochloric acid which results in the precipitation of a beige solid. The mixture is cooled and the precipitate filtered off and washed with diethyl ether. The crude product is recrystallised from ethanol to give 3-benzyloxy-1-carboxymethylpyrid-2-one (5.4g, 41%), m.p. 176-177°C.
- 3-Benzyloxy-1-carboxymethylpyrid-2-one (0.5 g) and N-hydroxysuccinimide (0.25 g) are dissolved in dimethylformamide (10 ml) and the solution cooled in an ice bath. Dicyclohexylcarbodiimide (0.45 g) dissolved in dimethylformamide (10 ml), is added to the pyridone and allowed to stand for 18 hours. The precipitated dicyclohexylurea is separated by filtration and the filtrate evaporated to dryness. The resultant residue is recrystallised from a methylene chloride/diethyl ether mixture to yield 3-benzyloxy-1-succinimyloxycarbonylmethylpyrid-2-one (0.56 g, 80%), m.p. 183-184°C.
- 3-Benzyloxy-1-succinimyloxycarbonylmethylpyrid-2-one (0.5 g) is dissolved in dimethylformamide (12.5 ml). To this solution is added a solution of 1,6-diaminohexane (0.5 molar equivalent) in methanol (5 ml). The resulting white precipitate is separated by filtration and the colourless filtrate is evaporated to dryness. The resultant residue is extracted with a chloroform/water mixture, the organic layer being dried (Na₂SO₄) and evaporated to dryness. The resultant residue is dissolved in ethanol containing 1% v/v of acetic acid and hydrogenated over palladium charcoal. Filtration, evaporation and recrystallisation from ethanol yields the title compound as a white crystalline solid in 70% yield, m.p. 240-242°C; νmax (nujol) 1645, 1580, 1555 cm¹; δ(d₆DMSO) 1.2 (s, 8H), 2.9 (s, 4H), 4.15 (s, 4H), 5.9 (t, 2H), 6.5 (d, 2H), 6.8 (d, 2H), 7.9 (t, 2H), 8.7 (s, 2H).
- 3-Benzyloxy-1-succinimyloxycarbonylmethylpyrid-2-one - prepared as described in Example 4 - is reacted with 1,8-diamino-octane in an analogous manner to that described for the reaction of this compound with 1,6-diaminohexane in Example 4 to yield the title compound in 76% yield, m.p. 238-239°C; νmax (nujol) 1650, 1580, 1560 cm⁻¹; δ(d₆DMSO) 1.2 (s, 12H), 4.4 (s, 4H), 5.9 (t, 2H), 6.6 (d, 2H), 6.9 (d, 2H), 8.0 (t, 2H), 8.8 (s, 2H).
- 3-Benzyloxy-2-methyl-4-pyrone (5.2 g, crude) is dissolved in a mixture of ethanol (100 ml) and water (200 ml) containing sodium hydroxide (2 g), the pH of the resulting solution being about 12 to 13. The tri-amine, N-(2-aminoethyl)-1,3-propanediamine (0.75 g), is then added to give a reaction mixture which contains a 3.75 molar excess of the 4-pyrone to tri-amine. The mixture is stirred at room temperature for 6 days and is then acidified with concentrated HCl to pH 2 and rotary evaporated to give a brown solid. This solid is extracted with ethanol from which a white solid is obtained on rotary evaporation. Recrystalliation from water gives N-[2-(3-hydroxy-2-methyl-4-oxopyrid-1-yl]-3-(3-hydroxy-2-methyl-4-oxopyrid-1-yl-propylamine (1.5 g). This product is hydrolysed by refluxing in 40% w/w HBr in CH₃CO₂H (ca 300 ml) on a steam bath for 30 minutes. The acids are removed by rotary evaporation (< 1 mm Hg) and water is added to the resulting oil to give a white precipitate. This precipitate is redissolved by heating and recrystallised by cooling to give the title compound(1) (0.66 g, 31%) as large elongated off-white crystalls of m.p. 137-140°C; γmax (nujol) 840, 1020, 1500, 1540, 1630 and 3400 cm⁻¹; δ(d₆DMSO) 2.2 (m, 2H), 2.5 (s, 3H), 3.1 (m, 2H), 3.5 (m,2H). 4.4-4.8 (m, 4H), 7.2 (d, 1H)) and 8.4 (d, 1H). (1) In a variation of this procedure the following alternative amines are prepared.
- The p-nitrophenyl ester of N-benzylglycine (2 g) and N-(2-aminoethyl)-1,3-propanediamine (0.18 g) are dissolved in ethylacetate (30 ml). After standing for 1 hour, the mixture is filtered, evaporated and resulting solid triturated with diethyl ether. Recrystallisation of the product from ethanol yields N-[2-(benzylaminoacetamido)-ethyl]-3-(benzylaminoacetamido)-propylamine as a solid, νmax (nujol) 1680, 1630, 1540 cm⁻¹; δ(d₆DMSO) 1.5 (quintet, 2H), 2.5 (m, 4H), 3.1 (q, 4H), 3.6 (d, 4H), 5.0 (s, 4H), 7.3 (s, 10H), 7.4 (m, 2H), 7.7 (m, 2H).
- Hydrogenation of this compound in ethanol containing 1% v/v of acetic acid over palladium/charcoal gives a 75% yield of the title compound as a viscous oil.
- The p-nitrophenyl ester of N-benzylglycine and N-(2-aminoethyl)-1,3-propane diamine are reacted in the same proportions as in (A) above but in dimethyl formamide as the solvent to yield, after working up in a similar manner, N-(N-benzylglycyl)-N-[2-(benzylaminoacetamido)-ethyl]-3-(benzylaminoacetamido)-propylamine in 65% yield, δ(d₆DMSO) 1.6 (m, 2H), 3.2 (m, 6H), 3.5 (d, 4H), 3.8 (d, 2H), 5.0 (s, 6H), 7.3 (s, 15H), 7.4 (m, 3H), 7.8 (m, 3H). Hydrogenation as in (A) above yields the title compound in 75% yield as an oil.
- The p-nitrophenyl ester of N-benzylglycine and N-(3-aminopropyl)-1,4-butane diamine are reacted together and the reaction mixture worked up in a similar manner to that described in (B) above for the reaction of this ester with N-(2-aminoethyl)-1,3-propanediamine to give N-(N-benzylglycyl)-N-[3-(benzylaminoacetamido)-propyl]-4-(benzylaminoacetamido)-butylamine, νmax (nujol) 1660, 1625 cm⁻¹; δ(d₆DMSO) 1.4 (m, 6H), 3.1 (m, 6H), 3.2 (s, 4H), 3.5 (d, 4H), 3.8 (d, 2H), 5.0 (s, 6H), 7.3 (s, 15H), 7.4 (m, 3H), 7.8 (m, 3H). Hydrogenation as in (A) above yields the title compound in 70% yield as an oil.
- The three amines prepared as described under (A), (B) and (C) are reacted with 3-benzyloxy-2-methyl-4-pyrone in an analogous manner to that described in this Example for N-(2-aminoethyl)-1,3-propanediamine to give, respectively, N-[2-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-ethyl]-3-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-propylamine, N-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetyl)-N-[2-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-ethyl]-3-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-propylamine and N-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetyl)-N-[3-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-propyl]-4-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-butylamine.
- 3-Benzyloxy-1-(2′-succinimyloxycarbonylethyl)-2-methylpyrid-4-one is prepared from 3-benzyloxy-1-carboxyethylpyrid-2-one by reaction with N-hydroxysuccinimide as described in Example 1, the compound being isolated in an analogous manner to that described in Example 4 for the corresponding 1-(2′-succinimyloxycarbonylethyl) compound. The compound is obtained in 60% yield as a solid of m.p. 144-146°C; νmax (nujol) 1800, 1770, 1735, 1625, 1570 cm⁻¹; δ(CDCl₃) 2.0 (s, 3H), 2.8 (s, 4H). 2.9 (t, 2H), 4.1 (t, 2H), 5.1 (s, 2H), 6.3 (d, 1H), 7.3 (s, 5H), 7.3 (d, 1H).
- 3-Benzyloxy-1-(2′-succinimyloxycarbonylethyl)-2-methylpyrid-4-one(0.5 g) is dissolved in methylene chloride (30 ml) and the solution is added dropwise over 15 minutes to spermidine [N-(3-aminopropyl-butylamine) (0.19 g) in methylene chloride (10 ml). The resulting solution is allowed to stand for 1 hour and is then washed with water, dried (Na₂SO₄) and evaporated to give N-[3-(3-benzyloxy-2-methyl-4-oxopyrid-1-ylacetamido)-propyl]-4-(3-benzyloxy-2-methyl-4- oxopyrid-1-ylacetamido)-butylamine in 70% yield as an oil, which on trituration with cold ethanol followed by recrystallisation from ethanol gives a white solid, m.p. 89°C; νmax (nujol) 3250, 1640, 1590 cm⁻¹; δ(d₆DMSO) 1.4 (m, 6H), 2.4 (s, 6H), 2.6 (m, 4H), 2.8 (m, 4H), 4.4 (t, 4H), 4.9 (s, 4H), 7.3 (s, 10H), 8.1 (m, 2H), 8.6 (d, 2H). Hydrogenation of this dibenzyl derivative over palladium/charcoal in ethanol containing 1% v/v acetic acid in an analogous fashion to that described in Example 4 yields the title compound as an oil.
- 3-Benzyloxy-1-succinimyloxycarbonylmethylpyrid-2-one - prepared as described in Example 4 - (2.1 g) is dissolved in dimethylformamide (50 ml) and tri-(2′-aminoethyl)-amine (0.3 g) is added with stirring. The resultant solution is stirred for 10 minutes and is then evaporated to dryness. The residue is extracted with methylene chloride/water, the organic layer being evaporated to dryness. The residue is dissolved in 95% ethanol and hydrogenated over palladium/charcoal, filtration and evaporation yielding a solid which is desiccated over solid NaOH. Recrystallisation of the desiccated solid from 95% ethanol yields the title compound (0.82 g, 68%) as a white solid, m.p. 112-114°C; νmax (nujol) 1650, 1590 cm⁻¹; δ(d₆DMSO) 2.3 (s, 6H), 2.95 (s, 6H), 4.4 (s, 6H), 5.9 (t, 3H), 6.55 (d, 3H), 6.9 (d, 3H), 8.0 (s, 3H).
- 3-Benzyloxy-1-(2′-succinimyloxycarbonylethyl)-2-methylpyrid-4- one - prepared as described in Example 7 - is reacted with tri-(2′-aminoethyl)-amine in an analogous procedure to that described in Example 8 for the reaction of the corresponding 1-(2′-succinimylcarbonylmethyl) compound. Working up in an analogous fashion gives N,N-di-(2-[3-(3-benzyloxy-2-methyl-4-oxopyrid-1-yl)-propionamido]-2-[3-(3-benzyloxy-2-methyl-4-oxopyrid-1-yl)-propionamido]-ethylamine in 45% yield as a thick viscous oil, δ(CDCl₃) 2.2 (s, 9H), 2.6 (t, 2H), 3.3 (m, 4H), 4.1 (t, 6H), 4.9 (s, 6H), 6.1 (d, 3H), 7.3 (s, 15H), 7.6 (d, 3H), 8.8 (m, 3H). Hydrogenation of this tribenzyl derivative over palladium/charcoal in ethanol containing 1% v/v acetic acid in an analogous fashion to that described in Example 8 yields the title compound.
- 3-Benzyloxy-1-succinimylcarbonylmethylpyrid-2-one - prepared as described in Example 4 - (2 g) is dissolved in dimethylformamide (50 ml) and a solution of N-(3-aminopropyl)-1,3-diaminopropane in methanol (20 ml) is added and the reaction mixture is allowed to stand overnight. Rotary evaporation yields an orange oil which is extracted with methylene chloride/water. The organic layer is dried, evaporated to dryness and desiccated over CaCl₂ to give N-(3-benzyloxy-2-oxopyrid-1-ylacetyl)-N-[3-(3-benzyloxy-2-oxopyrid-1-ylacetamido)-propyl]-3-(3-benzyloxy-2-oxopyrid-1-ylacetamido)-propylamine as an oil in 60% yield; δ(d₆DMSO) 1.6 (m, 4H), 3.0 (m, 8H), 4.3 (s, 6H), 4.75 (s, 6H), 6.0 (t, 3H), 6.8 (d, 3H), 7.1 (d, 3H), 7.3 (s, 15H), 8.3 (m, 2H). Hydrogenation of this tribenzyl derivative over palladium/charcoal in ethanol containing 1% v/v acetic acid in an analogous fashion to that described in Example 8 yields the title compound as an oil.
- The partition coefficient Kpart, being the ratio (concentration of compound in n-octanol)/(concentration of compound in aqueous phase) on partition between n-octanol and aqueous tris hydrochloride (20 mM, pH 7.4). is measured by spectrophotometry at 20°C for various of the compounds of the previous Examples and for their iron(III) complexes (at 10⁻⁴M). The solutions of the complexes are either produced, for compound 8, by dissolving the pre-formed complex prepared as described in Example 13, in the aqueous tris hydrochloride or, for compounds 5 and 10, by formation in the buffer in situ by the admixture of a 3:2 or 1:1 molar ratio, respectively, of the linked hydroxypyridone compound:ferric chloride, the pH thereafter being readjusted to 7.4 if necessary. Acid washed glassware is used throughout and, following mixing of 5 ml of the 10⁻⁴M aqueous solution with 5 ml n-octanol for 1 minute, the aqueous n-octanol mixture is centrifuged at 1,000 g for 30 seconds. The two resulting phases are separated for a concentration determination by spectrophotometry on each. For the metal-free linked hydroxypyridone compounds, the range 220-340 nm is used for concentration determinations whilst for the iron complexes, the range 340-640 nm is used.
- Values typical of those obtained are shown in Table 2, the compounds being identified by the same numbering system as that used in Table 1.
Table 2 Partition coefficients Compound Partition coefficient Kpart Free compound Iron complex [FeIII-(compound)₃] 5 0.017 0.10 8 0.02 0.03 10 0.2 0.3 - The iron complex of 1,6-di-(3-hydroxy-2-oxypyrid-1-ylacetamido)-hexane (compound 4: described in Example 4) is prepared by either procedure (a) or procedure (b).
- (a) An aqueous solution of 2 molar equivalents of ferric chloride is reacted for 5 minutes at room temperature with an aqueous solution containing 3 molar equivalents of 1,6-di-(3-hydroxy-2-oxyprid-1-ylacetamido)-hexane(1). The resultant solution is adjusted to pH 7.0 using 2 molar aqueous sodium hydroxide and is then freeze dried. The resulting powder is extracted with chloroform, filtered and the filtrate subjected to rotary evaporation to give an essentially quantitative yield of a complex containing the 1,6-di-(3-hydroxy-2-oxopyrid-1-ylacetamido)-hexane bivalent anion and the ferric cation. Recrystallisation of the complex from ethanol gives wine red coloured crystals, m.p. 300°C, νmax (nujol) 1520, 1610 cm⁻¹.
- (b) An ethanolic solution of 2 molar equivalents of ferric chloride is reacted for 5 minutes at room temperature with a chloroform solution containing 3 molar equivalents of 1,6-di-(3-hydroxy-2-oxopyrid-1-ylacetamido)-hexane(1). The resultant solution is neutralised by the addition of solid sodium carbonate, the precipitated sodium chloride removed by filtration and the filtrate evaporated to give an essentially quantitative yield of a complex containing the 1,6-di-(3-hydroxy-2-oxopyrid-1-ylacetamido)-hexane bivalent anion and the ferric cation, m.p. > 300°C.
- N,N-[2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethyl]-2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethylamine (compound 8: described in Example 8) is reacted with ferric chloride in a 1:1 molar ratio by either procedure (a) or (b) above to give the neutral iron(III) containing the N,N-[2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethyl]-2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethylamine trivalent anion and the ferric cation in 1:1 proportion. This complex is obtained as wine red coloured crystals, m.p. > 300°C, νmax (nujol) 1530, 1580(w), 1620(w) and 1660 cm⁻¹.
- The accumulation of iron by human erythrocytes which are associated with the iron complexes of three compounds described in earlier Examples was studied by incubating for 1 hour at 37°C a 5% suspension of erythrocytes in a medium consisting of the ⁵⁹Fe labelled iron complex(1) (10⁻³ M) in aqueous sodium chloride (130 mM) buffered to pH 7.4 by tris hydrochloride (2 ml). Following this period of incubation, an aliquot of the erythrocyte/medium mixture was placed above a layer of silcone oil and the erythrocytes separated by centrifugation through the oil. The ⁵⁹Fe levels associated with the erythrocytes and the incubation medium were then counted. By way of comparison, a similar experiment was concluded with ferric citrate. The results obtained are shown in Table 3 where the amount of the complex entering erythrocytes (n.mole) is given, the quoted values being in each case the mean of at least three determinations. It will be seen that each of the iron complexes compares well with ferric citrate.
(1)The iron complexes of the compounds are prepared in situ in the buffered solution using the compound and Fe⁵⁹Cl₃ in exactly similar ratios to those described in Example 12 for compounds 4 and 8, and for compound 5 in the same ratio as described in that Example for compound 4. -
Table 3 Uptake of complexes by erythrocytes Compound Amount of complex entering erythrocytes (n.mole) FeIII complex of compound 4 52 FeIII complex of compound 5 85 FeIII complex of compound 8 45 FeIII citrate < 5 - The iron uptake into the serosal space of the inverted rat jejunal sac was compared for the iron complexes of two compounds described in earlier Examples. Rats (male Sprague Dawley, 60 g) were killed and the jejunum removed, everted and cut into three segments (4 cm length). The segments were tied at both ends and filled with Krebs Ringer buffer (0.2 ml) and incubated in Krebs Ringer buffer containing ⁵⁹Fe complexes at 37°C for periods up to 1 hour (the iron complexes were prepared in situ by an analogous procedure to that described in Example 12). The content of the sac was counted for ⁵⁹Fe and measured spectrophotometrically.
- The results obtained for the two iron complexes according to the present invention and, by way of comparison, for ferric citrate (this being on iron compounds which is contained in preparations marketed for the treatment of iron deficiency anaemia) are shown in Table 4, the iron uptake for each compound being shown relative to that for ferric chloride as 1. It will be seen that the complexes of the present invention each provide a level of iron uptake which is significantly higher than the level observed for ferric citrate.
Table 4 Compound Relative Iron Uptake FeCl₃ 1 FeIII complex of compound 5 15 FeIII complex of compound 8 11 FeIII citrate 2
(1)The concentration of the linked hydroxypyridone compound is 0.1M although this figure may be varied, for example in a range of 0.01 to 0.05M, being constrained at the upper end of the range by the solubility of the compound in the reaction solvent.
(1)The concentration of the linked hydroxypyridone compound is 0.1M although this figure may be varied, for example in a range of 0.01 to 0.05M, being constrained at the upper end of the range by the solubility of the compound in the reaction solvent.
Claims (21)
- An iron complex of a compound containing 2 to 100 rings carrying adjacent hydroxy and oxo groups, said rings being selected from 3-hydroxypyrid-2-ones, 3-hydroxypyrid-4-ones and 1-hydroxypyrid-2-ones and being covalently linked to each other with retention of their adjacent hydroxy and oxo groups through linking groups which are either wholly of a hydrocarbon nature or which additionally contain one or more of the same or different groups selected from -O-, -S-, -NH-,
- A complex according to Claim 1, in which the linked rings are substituted or unsubstituted 3-hydroxypyrid-2-ones and/or 3-hydroxypyrid-4-ones.
- A complex according to Claim 1 or 2, in which the rings are either unsubstituted apart from linking groups or are additionally substituted only by an aliphatic hydrocarbon group of 1 to 6 carbon atoms on one or more ring carbon atoms.
- A complex according to Claim 1, 2 or 3, in which the rings are either unsubstituted apart from linking groups or are additionally substituted only on one ring carbon atom.
- A complex according to Claim 2, in which the rings are selected from 2-methyl-3-hydroxypyrid-4-one and unsubstituted 3-hydroxypyrid-2-one.
- A complex according to any of the preceding claims, which contains 2 to 10 rings.
- A complex according to Claim 6, which contains 2, 3 or 4 rings.
- A complex according to Claim 7, which contains 3 rings.
- A complex according to Claim 7, in which two or three 3-hydroxypyrid-2-one or 3-hydroxypyrid-4-one rings are linked through the nitrogen atoms thereof.
- A complex according to Claim 9, in which the rings are 3-hydroxypyrid-2-one rings with their nitrogen atoms separated by 8 to 10 atoms.
- A complex according to Claim 9, in which the rings are 3-hydroxypyrid-4-one rings with their nitrogen atoms separated by 9 to 12 atoms.
- A complex according to Claim 7, in which two 3-hydroxypyrid-2-one or two 3-hydroxypyrid-4-one rings are linked through the nitrogen atoms thereof by a group -(CH₂)n-, -(CH₂)a-NH-(CH₂)b-, -(CH₂)c-CONH-(CH₂)d-NHCO-(CH₂)c or -(CH₂)c-CONH-(CH₂)e-NH-(CH₂)f-NHCO-(CH₂)c-, wherein n is an integer from 6 to 12, a and b are each separately an integer from 2 to 6, c is an integer from 1 to 3, d is an integer from 2 to 8, and e and f are each separately an integer from 2 to 4.
- A complex according to Claim 13, in which n is 8 to 10; a and b are each separately 2 to 5; c is 1 and d is 6 or c is 2 and d is 2 or 4; and c is 1, e is 2 and f is 3 or c is 2, e is 2 and f is 2.
- A complex according to Claim 15, in which c is 1, e is 2, f is 3 and g is 1, or c is 1, e is 3, f is 4 and g is 1, or c is 1, e is 3, f is 4 and g is 2.
- A complex according to Claim 1, in which the compound is N-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetyl)-N-[2-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-ethyl]-3-(3-hydroxy-2- methyl)-4-oxopyrid-1-ylacetamido)-propylamine, N-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetyl)-N-[3-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-propyl]-4-(3-hydroxy-2-methyl-4-oxopyrid-1-ylacetamido)-butylamine, N,N-di-(2-[3-(3-hydroxy-2-methyl-4-oxopyrid-1-yl)-propionamido]-ethyl)-2-[3-(3-hydroxy-2-methyl-4oxopyrid-1-yl)-propionamido]-ethylamine, N,N-di-[2-(3-hydroxy-2oxopyrid-1-ylacetamido)-ethyl]-2-(3-hydroxy-2-oxopyrid-1-ylacetamido)-ethylamine, or N-(3-hydroxy-2-oxopyrid-1-ylacetyl)-N-[3-(3-hydroxy-2-oxopyrid-1-ylacetamido)-propyl]-3-(3-hydroxy-2oxopyrid-1-ylacetamido)-propylamine.
- An iron complex of a compound according to any of Claims 8 and 15 to 17, being the neutral 1:1 complex containing 1 molar proportion of iron(III) and 1 molar proportion of the anion of the linked three ring compound.
- A pharmaceutical composition comprising an iron complex according to any of Claims 1 to 18, together with a physiologically acceptable diluent or carrier.
- An iron complex according to any of Claims 1 to 18, for use in therapy.
- The use of an iron complex according to any of Claims 1 to 18 for the manufacture of a medicament for use in increasing the level of iron in a patient's bloodstream.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8325494 | 1983-09-23 | ||
GB838325494A GB8325494D0 (en) | 1983-09-23 | 1983-09-23 | Pharmaceutical compositions |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84306438A Division-Into EP0138421B1 (en) | 1983-09-23 | 1984-09-20 | Hydroxypyridone derivatives and pharmaceutical compositions containing them |
EP84306438A Division EP0138421B1 (en) | 1983-09-23 | 1984-09-20 | Hydroxypyridone derivatives and pharmaceutical compositions containing them |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0357150A1 EP0357150A1 (en) | 1990-03-07 |
EP0357150B1 true EP0357150B1 (en) | 1993-12-08 |
Family
ID=10549200
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84306438A Expired - Lifetime EP0138421B1 (en) | 1983-09-23 | 1984-09-20 | Hydroxypyridone derivatives and pharmaceutical compositions containing them |
EP89202213A Expired - Lifetime EP0357150B1 (en) | 1983-09-23 | 1984-09-20 | Pharmaceutical compositions |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP84306438A Expired - Lifetime EP0138421B1 (en) | 1983-09-23 | 1984-09-20 | Hydroxypyridone derivatives and pharmaceutical compositions containing them |
Country Status (10)
Country | Link |
---|---|
US (1) | US4666927A (en) |
EP (2) | EP0138421B1 (en) |
JP (2) | JPH062739B2 (en) |
CY (1) | CY1516A (en) |
DE (2) | DE3483713D1 (en) |
DK (1) | DK158349C (en) |
GB (2) | GB8325494D0 (en) |
GR (1) | GR80445B (en) |
SG (1) | SG80989G (en) |
ZA (1) | ZA847408B (en) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8308055D0 (en) * | 1983-03-24 | 1983-05-05 | Hider R C | Pharmaceutical compositions |
GB8308054D0 (en) * | 1983-03-24 | 1983-05-05 | Hider R C | Pharmaceutical compositions |
US4780238A (en) * | 1983-08-25 | 1988-10-25 | The United States Of America As Represented By The United States Department Of Energy | Natural chelating agents for radionuclide decorporation |
US5010191A (en) * | 1985-08-19 | 1991-04-23 | The Regents Of The University Of California | Imaging agents for in vivo magnetic resonance and scintigraphic imaging |
US4908371A (en) * | 1987-11-10 | 1990-03-13 | Ciba-Geigy Corporation | Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload |
GB8910521D0 (en) * | 1989-05-08 | 1989-06-21 | Nat Res Dev | The stabilization of organic compounds |
US5393777A (en) * | 1990-11-15 | 1995-02-28 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Deferration using anguibactin siderophore |
WO1992013841A1 (en) * | 1991-02-08 | 1992-08-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Complexing agents |
AU4562693A (en) * | 1992-07-01 | 1994-01-31 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Contrast agents for mr diagnosis |
US5298525A (en) * | 1992-11-23 | 1994-03-29 | University Technologies International, Inc. | Diabetes prevention and treatment |
US5849587A (en) * | 1995-06-09 | 1998-12-15 | Cornell Research Foundation, Inc. | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells |
AU6010696A (en) | 1995-06-10 | 1997-01-09 | Vitra Pharmaceuticals Ltd | Iron compounds, compositions, methods of making the same and uses thereof |
DK0840727T3 (en) * | 1995-06-14 | 2004-08-16 | Univ California | 3-hydroxy-2 (1 H) -pyridinone-chelating agents |
US7026116B1 (en) * | 1996-04-04 | 2006-04-11 | Bio-Rad Laboratories, Inc. | Polymorphisms in the region of the human hemochromatosis gene |
US6140305A (en) * | 1996-04-04 | 2000-10-31 | Bio-Rad Laboratories, Inc. | Hereditary hemochromatosis gene products |
US6849399B1 (en) | 1996-05-23 | 2005-02-01 | Bio-Rad Laboratories, Inc. | Methods and compositions for diagnosis and treatment of iron misregulation diseases |
ZA976421B (en) * | 1996-07-22 | 1998-01-22 | Boehringer Mannheim Italia | New bis-platinum complexes with polyamine ligands as antitumor agents. |
GB9625638D0 (en) * | 1996-12-10 | 1997-01-29 | Cenes Ltd | Therapeutic antioxidants for alzheimer's diease |
JP2002506438A (en) | 1997-06-13 | 2002-02-26 | プロジェニター,インコーポレーテッド | Methods and compositions for diagnosing and treating iron overload and iron deficiency |
GB2345058A (en) * | 1998-12-01 | 2000-06-28 | Cerebrus Pharm Ltd | Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system |
US6767741B1 (en) * | 1999-08-27 | 2004-07-27 | Invitrogen Corporation | Metal binding compounds and their use in cell culture medium compositions |
CA2421410C (en) * | 2000-09-19 | 2009-11-10 | Vitra Pharmaceuticals Limited | Iron compositions |
US6846915B2 (en) * | 2001-08-13 | 2005-01-25 | The Regents Of The University Of California | Hydroxypyridonate and hydroxypyrimidinone chelating agents |
GB0211500D0 (en) | 2002-05-18 | 2002-06-26 | Vitra Pharmaceuticals Ltd | Method of forming iron hydroxypyrone compounds |
US7595073B2 (en) * | 2003-02-28 | 2009-09-29 | Kraft Foods Global Brands Llc | Use of siderophores and organic acids to retard lipid oxidation |
GB0425555D0 (en) * | 2004-11-19 | 2004-12-22 | Glaxo Group Ltd | Novel compounds |
WO2008008797A2 (en) * | 2006-07-10 | 2008-01-17 | The Regents Of The University Of California | Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides |
US9259670B2 (en) | 2008-04-16 | 2016-02-16 | The University Of Kentucky Research Foundation | Flow-through filter to remove aluminum from medical solutions |
US9139456B2 (en) | 2008-04-16 | 2015-09-22 | The Curators Of The University Of Missouri | Chelating compounds and immobilized tethered chelators |
US7932326B2 (en) * | 2008-04-16 | 2011-04-26 | The University Of Kentucky Research Foundation | Chelating compounds and immobilized tethered chelators |
US20100008864A1 (en) * | 2008-07-10 | 2010-01-14 | Andreas Meijer | Aromatic multimers |
EP2816038B8 (en) | 2009-08-24 | 2019-12-25 | Lumiphore, Inc. | Hopo chelators |
WO2011079291A1 (en) * | 2009-12-24 | 2011-06-30 | Lumiphore, Inc. | Radiopharmaceutical complexes |
US11453652B2 (en) | 2013-03-15 | 2022-09-27 | Lumiphore, Inc. | Di-macrocycles |
CN106928132B (en) * | 2017-02-23 | 2020-07-24 | 苏州大学 | Hydroxypyridone ligand and application thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3968118A (en) * | 1968-08-31 | 1976-07-06 | Hoechst Aktiengesellschaft | Process for the manufacture of 1-hydroxy-2-pyridones |
CA1049411A (en) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | N-substituted pyridone and general method for preparing pyridones |
CY1501A (en) * | 1982-03-24 | 1990-08-03 | Nat Res Dev | Pharmaceutical compositions containing a complex of iron with n-substituted 3-hydroxypyrid-2-one or-4-one derivatives |
GB2118176B (en) * | 1982-03-24 | 1985-12-04 | Nat Res Dev | Pharmaceutical compositions |
GR78491B (en) * | 1982-03-24 | 1984-09-27 | Nat Res Dev |
-
1983
- 1983-09-23 GB GB838325494A patent/GB8325494D0/en active Pending
-
1984
- 1984-09-18 US US06/651,684 patent/US4666927A/en not_active Expired - Fee Related
- 1984-09-20 EP EP84306438A patent/EP0138421B1/en not_active Expired - Lifetime
- 1984-09-20 CY CY1516A patent/CY1516A/en unknown
- 1984-09-20 GB GB08423799A patent/GB2146989B/en not_active Expired
- 1984-09-20 DE DE8484306438T patent/DE3483713D1/en not_active Expired - Lifetime
- 1984-09-20 ZA ZA847408A patent/ZA847408B/en unknown
- 1984-09-20 EP EP89202213A patent/EP0357150B1/en not_active Expired - Lifetime
- 1984-09-20 DE DE89202213T patent/DE3486255T2/en not_active Expired - Fee Related
- 1984-09-21 GR GR80445A patent/GR80445B/en unknown
- 1984-09-21 DK DK453684A patent/DK158349C/en not_active IP Right Cessation
- 1984-09-25 JP JP59201408A patent/JPH062739B2/en not_active Expired - Lifetime
-
1989
- 1989-12-12 JP JP1324877A patent/JPH062740B2/en not_active Expired - Lifetime
- 1989-12-16 SG SG809/89A patent/SG80989G/en unknown
Non-Patent Citations (1)
Title |
---|
CHEMICAL ABSTRACTS vol. 93, no. 13, 29 September 1980, page 504, column 2, abstract no. 130476r, Columbus, Ohio, USA; J Itoh et al.: "Studies on antibiotics BN-227 and BN-227-F, new antibiotics. I. Taxonomy, isolation and characterization" * |
Also Published As
Publication number | Publication date |
---|---|
DK158349C (en) | 1990-10-15 |
JPH062740B2 (en) | 1994-01-12 |
GB2146989A (en) | 1985-05-01 |
JPH02191254A (en) | 1990-07-27 |
US4666927A (en) | 1987-05-19 |
SG80989G (en) | 1990-07-06 |
JPH062739B2 (en) | 1994-01-12 |
EP0138421A3 (en) | 1987-06-03 |
EP0138421A2 (en) | 1985-04-24 |
ZA847408B (en) | 1986-05-28 |
DK453684A (en) | 1985-03-24 |
GB2146989B (en) | 1987-02-18 |
DE3483713D1 (en) | 1991-01-17 |
DE3486255T2 (en) | 1994-03-24 |
CY1516A (en) | 1990-08-03 |
EP0357150A1 (en) | 1990-03-07 |
GR80445B (en) | 1985-01-23 |
EP0138421B1 (en) | 1990-12-05 |
DK158349B (en) | 1990-05-07 |
GB8325494D0 (en) | 1983-10-26 |
GB8423799D0 (en) | 1984-10-24 |
DK453684D0 (en) | 1984-09-21 |
JPS6094965A (en) | 1985-05-28 |
DE3486255D1 (en) | 1994-01-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0357150B1 (en) | Pharmaceutical compositions | |
US5104865A (en) | Iron complexes of hydroxypyridones useful for treating iron overload | |
EP0138420B1 (en) | Pharmaceutical compositions containing 1-hydroxypyrid-2-one derivatives | |
EP0120670B1 (en) | Iron iii complexes of hydroxypyridones, and their pharmaceutical compositions | |
US5624901A (en) | 3-hydroxy-2(1H)-pyridinone chelating agents | |
EP0145228B1 (en) | Pharmaceutical compositions | |
JPH0680637A (en) | Compound used for medicinal composition | |
EP0094149B1 (en) | Pharmaceutical compositions containing a complex of iron with n-substituted 3-hydroxypyrid-2-one or -4-one derivatives | |
US5177068A (en) | Pharmaceutical compositions | |
US5281578A (en) | Gallium compounds | |
EP1506183B1 (en) | Method of forming iron hydroxypyrone compounds | |
EP0159194A2 (en) | Iron 3-hydroxypyrone or 3-hydroxypyridone complexes and pharmaceutical compositions containing them | |
USRE34313E (en) | Pharmaceutical compositions | |
GB2117766A (en) | Pharmaceutical compositions | |
EP0305646B1 (en) | 3-Hydroxypyrid-4-ones and pharmaceutical compositions | |
KR970009042B1 (en) | 1.4.10.13 - tetraoxa -7.16-diazacycloactadecane derivatives and pharmaceutical compositions containing them | |
EP0003897A1 (en) | Phosphinegold(I)salts, process for their preparation and compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 138421 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): BE CH DE FR GB IT LI NL SE |
|
17P | Request for examination filed |
Effective date: 19900504 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BRITISH TECHNOLOGY GROUP LTD |
|
17Q | First examination report despatched |
Effective date: 19930323 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): BE CH DE FR IT LI NL SE |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 138421 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): BE CH DE FR IT LI NL SE |
|
ITF | It: translation for a ep patent filed | ||
REF | Corresponds to: |
Ref document number: 3486255 Country of ref document: DE Date of ref document: 19940120 |
|
ET | Fr: translation filed | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
EAL | Se: european patent in force in sweden |
Ref document number: 89202213.8 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19950814 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19950817 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 19950919 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19950926 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19950929 Year of fee payment: 12 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19951005 Year of fee payment: 12 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Effective date: 19960921 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Effective date: 19960930 Ref country code: FR Effective date: 19960930 Ref country code: CH Effective date: 19960930 Ref country code: BE Effective date: 19960930 |
|
BERE | Be: lapsed |
Owner name: BRITISH TECHNOLOGY GROUP LTD Effective date: 19960930 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Effective date: 19970401 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 19970401 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Effective date: 19970603 |
|
EUG | Se: european patent has lapsed |
Ref document number: 89202213.8 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |